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ABSTRACT 
  
The molecular events associated with the recurrence of castration resistant prostate 
cancer (CRPC) are of critical importance in prostate cancer research, as CRPC is 
associated with high morbidity and lethality.  CRPC is associated with deregulated 
prostatic epithelium exhibiting decreased AR expression in over 30% of the cases and 
seems to mimic the proliferative AR-negative undifferentiated transit amplifying (T/A) 
cells of the developing prostate.  In an effort to further characterize this proliferative and 
undifferentiated cell population, we evaluated possible mechanisms involved in AR gene 
repression.    
 We have shown that E2F1, a known transcriptional activator, represses AR 
expression. To explore this mechanism further, we overexpressed E2F1 in prostate 
epithelial cells and found that AR levels decreased while a dominant negative E2F1 
construct reversed the inhibitory effects on AR transcription. E2F1 activates the 
transcription of DNMT1, a protein that typically silences genes through DNA 
methylation, however, we found that DNMT1 repressed the AR gene in a DNA 
methylation independent fashion.   
 We further explored the E2F1/DNMT1/AR regulatory axis in a CRPC 
mouse model.  Heightened E2F1 expression was previously shown to be inversely 
correlated with AR expression during human prostate cancer progression to CRPC.  We 
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demonstrated that DNMT1 nuclear staining significantly increased from benign tissue to 
treatment resistant, metastatic prostate cancer in humans.  Considering that abnormal   
levels of DNMT1 may methylate and repress AR, we evaluated tissue from CRPC mice 
injected with a DNA methylation inhibitor, 5-aza. A rise in AR positive tissue 
corresponded with a decrease in the amount of DNMT1 nuclear staining following 
treatment.  The immunohistochemical data suggests that hypermethylation mediated 
repression of the AR gene by DNMT1 during the development of CRPC may represent 
an important etiological aspect of this disease.   
 In summary, we have identified a mechanism of AR repression mediated 
by the E2F1/DNMT1 axis that results in methylation independent AR repression in 
proliferative, undifferentiated prostate epithelium.  However, AR repression also 
identified in neoplastic cells appears to be dependent on DNA methylation during the 
emergence of CRPC. Our studies reveal novel epigenetic regulatory mechanisms 
involved in AR repression that may further elucidate the understanding of transcriptional 
regulation, particularly in CRPC.  
CHAPTER I 
 
INTRODUCTION 
 
It is estimated that prostate cancer will be the second leading cause of cancer deaths in 
2011 (1). As of 2006, the 5 year relative survival rate for patients with local and regional 
prostate cancer was 100%, while the survival rate for patients with metastatic disease was 
30% (1).  Elderly men continue to be at risk for the disease, considering that 97% of all 
prostate cancer cases occur at the age of 50 years or older (1).  The heterogeneous 
pathology of prostate cancer has complicated efforts to classify the disease into treatable 
subtypes.  Prostate tissue lesions already contain multiple foci with inconsistent allelic 
abnormalities during the pre-cancerous stage known as prostate intraepithelial neoplasia 
(PIN) (2).  Prostate cancer additionally has an array of unusual morphological variants 
histologically defined as endometrioid adenocarcinoma, pseudohyperplastic carcinoma, 
foamy gland carcinoma, and adenocarcinoma with paneth-like cells (3).  Continued 
analysis of the molecular events associated with prostate cancer initiation and progression 
may reveal targetable pathways that define specific prostate cancer subsets.   
 
Prostate Development and Differentiation in an AR Dependent Context 
A more thorough comprehension of the regulatory mechanisms during prostate 
development and differentiation might reveal processes that are potentially deregulated 
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during prostate tumorigenesis.  Currently the prostate is known to emanate from the 
urogenital sinus below the bladder rudiment as small epithelial buds.  The epithelium 
continues to branch out into the surrounding mesenchyme, developing solid cords of 
undifferentiated epithelium.  The cells of each strand eventually stratify and form tubes 
composed of an inner luminal and outer basal layer.  The mesenchyme surrounding the 
prostate epithelium differentiates into stromal smooth muscle (as reviewed in (4)).  
Androgenic hormones are required for the development of a fully functional prostate.   
Prostate formation depends on adequate levels of the circulating androgen, 
testosterone (T).  The prostate fails to grow in developing females that normally have low 
levels of T, however prostate epithelial buds emanate from extracted female mouse 
urogenital sinus (UGS) after 36h of T stimulation (5).  The ability of T to establish a 
prostate is dependent on the enzymatic activity of 5-alpha-reductase.  The reduction of T 
by this enzyme results in the formation of dihydrotestosterone (DHT), which is essential 
during prostate development (as reviewed in (6)).  Both T and DHT function to regulate 
prostate growth and continued morphogenesis through the activation of the androgen 
receptor (AR). 
 AR is a member of the steroid receptor family and functions as a transcription 
factor upon hormone ligand binding.  The receptor is composed of a transactivation 
domain at the N-terminal followed by 4 highly conserved regions (DNA binding, 
translocation, and ligand binding domain (as reviewed in (7)).  In the absence of either T 
or DHT, AR localizes to the cytoplasm and associates with heat-shock proteins (HSP) 
that obstruct access to the DNA binding domain.  Hormone interactions with the ligand 
binding domain induce conformational changes that facilitate hsp dissociation and 
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exposure of the translocation domain.  The hormone bound receptor undergoes both 
dimerization and phosphorylation before entering the nucleus (as reviewed in (8)). Once 
in the nucleus, the transactivation domain interacts with co-regulators to direct the 
transcription of target genes involved in proliferation, differentiation, morphogenesis and 
cell signaling (9-11).   
 The embryonic development of the prostate requires AR expression in the stromal 
tissue surrounding the epithelial buds of the rudimentary prostate (as reviewed in (12)).  
Activated AR transcribes stromal autocrine and paracrine signaling factors, referred to as 
andromedins, that coordinate the stratification and canalization of UGS epithelium into a 
pre-pubertal prostate (as reviewed in (13)).  Fibroblast growth factors (FGF) are 
suggested to function as andromedins that regulate cell growth and proliferation 
(Figure1.1).  Treatment of rat ventral prostate, with FGF7 in culture, was shown to induce 
the growth of branching prostate epithelial ducts in the absence of androgens (14). The 
expression of unique receptors at the cell membrane further specifies the cellular 
response to FGF signaling.  The expression of various FGF receptor-2 isoforms was 
specifically associated with different levels of cellular proliferation (15). The cell 
signaling events that are relayed between the mesenchyme and prostate epithelium are 
still ambiguous. However, the study of andromedins has helped define an intermediary 
mechanism utilized by the AR to stimulate cellular proliferation and differentiation.   
 It is generally agreed upon that the various populations of prostate epithelium 
share similar origins.  English et al demonstrated that upon castration 94% of rat ventral 
prostate epithelium was lost due to cell death. However the remaining cells were still able 
to reproduce and remodel a functioning prostate after the re-installment of androgens 
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(16).  The identification of an androgen independent, self-renewing cell within the basal 
epithelium implied that a prostate stem cell may exist. Many studies have tried to 
uniquely define a unique prostate epithelial stem cell through the use of molecular 
markers.  The current molecular profile, CD133+CD44alpha2beta1hiCK5+/18+, 
distinguishes putative epithelial stem cells from others (as reviewed in (17)), but 
similarities with newly defined progenitors require identifiers with higher specificity.  
The requirement for androgens to regenerate castration depleted prostates suggests that 
the differentiation of prostate epithelial stem cells into the various cell types is dependent 
on androgen signaling.  The actual signaling events involved in cell specific 
differentiation are unknown, but a stem cell population is assumed to re-establish the 
prostate.   
Prostate stem cells differentiate into a set of cells that have become assigned to 
either the basal or luminal layer (Figure 1.1).  The basal layer is defined by the expression 
of cytokeratins (CK) 14 and 5, while the luminal layer is predominantly CK8+/18+ (18).  
Neuroendocrine cells residing in the basal layer have long dendritic extensions that 
invade the luminal layer.  Rare neuroendocrine cells secrete peptide hormones and 
biogenic amines that may stimulate proliferation (as reviewed in (19)).  Transit 
amplifying (T/A) cells which also originate in the basal layer uniquely express p63 and 
have a limited number of cell divisions before transitioning to the next cell type (20). 
Intermediate cells, which express both basal (CK14+/5+) and luminal (express AR 
mRNA) markers, are characterized by the expression of prostate stem cell antigen 
(PSCA) (21).  Functional AR expression is a defining characteristic of prostate luminal 
cells. Activation of AR within the cells is observed by the secretion of prostate specific 
4
  
Figure 1.1 Model of epithelial cell differentiation in the prostate gland.  (A) The 
activation of stromal expressed AR by DHT results in the release of paracrine factors 
(andromedins/growth factors) that facilitate epithelial differentiation.  Prostate stem cells 
that are cytokeratin (K) 5
+
/14
+
 either self-renew or differentiate into either T/A 
amplifying cells or neuroendocrine cells in the basal layer.  T/A cells transition to 
intermediate cells that eventually terminally differentiate into the luminal epithelium 
(K18
+
).  (B) Schematic diagram of a prostate gland with a section undergoing cellular 
differentiation.  The brown cells are representative of the basal layer.  The graphical key 
defines the components depicted in (A) and (B). 
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antigen (PSA) which results from the targeted transcription of the Kallikrein 3 (KLK3) 
gene.  A differentiation model presented by John Isaacs proposes two cell fate pathways 
for the prostate epithelial stem cell.  One involves the differentiation of the cell into rare 
neuroendocrine cells, while the second transition into T/A cells further progresses 
through an intermediary state before terminally differentiating into luminal secretory cells 
(22).  Further differentiation functions to limit the rates of cellular division observed in 
early development.  AR negative T/A cells have a high proliferative index, while the 
terminally differentiated luminal cells express elevated AR levels. 
 High levels of activated AR in the luminal epithelium induce an anti-proliferative 
program.  DHT was shown to slow the growth of AR overexpressing rat prostate cell 
lines, while AR negative cells were unaffected by the treatment (23). Directed expression 
of functional AR in both malignant and non-transformed AR negative human cell lines 
(PC-3 and BPH-1) reduced proliferation following androgen stimulation (24, 25).  
Activated AR in prostate epithelial cells may slow cellular division by stimulating 
pathways that upregulate either p27kip1 or p21/waf1 cyclin dependent kinases.  A study 
demonstrated that the anti-proliferative effect of melatonin on minimally transformed 
prostate epithelial cells requires the transcriptional upregulation of p27
kip1
 by AR (26).  
Additionally, reduced  proliferation of LNCaP cells by vitamin D was mediated by 
p21/waf1 in an AR dependent manner (27).  Considering that p21 is upregulated through 
the binding of activated AR to androgen response elements in the promoter (28), AR may 
target p21 to inhibit proliferation. The antagonistic effects of normal functioning AR on 
proliferation suggest that AR expression, during the differentiation of AR negative T/A 
cells, inhibits further cell division.  AR may be silenced in T/A cells in order to maintain 
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a high proliferative potential.  The mechanisms that allow for such a proliferative 
characteristic in T/A cells would likely benefit the survival of tumor cells as well.  
 
Mechanisms of Cellular Proliferation 
Cell division is regulated in a cyclical manner coordinated by the cooperation of a diverse 
set of genes.  Periods of DNA replication and a cell division respectively known as the S 
and M-phase are separated by two preparatory G-phases (1 and 2), while  non-dividing 
cells exist in a quiescent state known as G0 (as reviewed in (29)).  Various checkpoints 
modulate cell cycle progression in order to reduce cellular abnormalities.  One of the 
major cell cycle checkpoint regulators was discovered from studies of retinoblastomas.  
Genetic mutations in the RB1 gene were identified as the primary defect predisposing 
patients to retinal tumors (30) and have become associated with many human cancers 
(31-33).  RB1 encodes a protein which may be involved in prostate cancer progression.  
Conditional RB1 allele deletions were shown to induce a pre-carcinogenic state in mouse 
prostate epithelium (34).  Additionally, increased Rb protein (pRb) deficiencies were 
observed during metastatic prostate cancer (35).  Studies showing that RB1 gene 
irregularities lead to abnormal cell division support a role for pRb in cell cycle 
checkpoint regulation. 
 Rb controls the G1/S-phase checkpoint by regulating the targeted transcription of 
S-phase activating genes.  Rb, as a pocket protein (p107 and p130) family member, 
possesses a highly conserved binding domain capable of associating with multiple 
proteins (as reviewed in (36)).  The interaction between hypophosphorylated pRb and 
E2F transcription factors (E2F1-3) (37) particularly inhibits cell cycle progression.   The 
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transcription factors, while sequestered by hypophosphorylated pRb, are unable to target 
the transcription of genes required for the G1 to S-phase transition (38).  Phosphorylation 
of pRb by cyclin dependent kinases disrupt pRb/E2F interactions and promote cell cycle 
progression (as reviewed in (39)).  Rb protein plays a vital role in maintaining normal 
proliferation through control of the G1/S-phase checkpoint.  Regulation of the E2F1 
transcription factor by pRb is especially important, considering that the transcription 
factor is capable of inducing hyperproliferation. 
 E2F1 is a member of a functionally diverse set of transcription factors.  E2Fs 1-3 
generally activate transcription while E2Fs 4-8 function to repress transcription (as 
reviewed in (40)). E2F1 shares a set of conserved domains with E2Fs 2-3 that include a 
nuclear localization sequence, DNA binding, dimerization protein (DP), and Rb binding 
included transactivation domain (as reviewed in (41)).  The heterodimerization of either 
DP-1 or 2 with E2F1 through the DP-dimerization domain facilitates transcriptional 
activity that is inhibited by additional interactions with pRb (42).  Subsequent DP-1 
phosphorylation is facilitated by the interaction between E2F1 and the cyclinA/cdk2 
complex at the cyclinA/cdk2 binding domain and is required for normal S-phase 
progression (43).  Although a majority of E2F1 initiated transcription occurs through 
contacts made between the DNA binding domain and the E2F responsive sequences (44), 
association with alternate factors may assist DNA binding independent transcription. 
E2F1 N-terminal interactions with Sp-1 (45) were shown to allow for the transcriptional 
activation of an Sp-1 consensus site containing c-myc promoter (46).  Other undefined 
E2F1 interacting proteins may drive transcription by recruiting E2F1 to target gene 
promoters.   
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E2F1 targets a spectrum of genes with multiple cell functions. Transcriptional 
targets have been identified under varying cell context dependent conditions.  A 2,500 
gene microarray created from the livers of newborn mice demonstrated that gene 
expression, in most cases, was minimally altered between E2F1 mutant versus wild type 
mice.  However, significant transcriptional changes resulting from the loss of E2F1 were 
observed in a small cohort of functionally undefined genes (47).  Alternatively, induced 
expression of E2F1 in a non-transformed primary osteosarcoma cell line (Saos-2) 
increased the transcription of genes involved in cell cycle and growth regulation, 
angiogenesis, apoptosis, and cancer progression (48).  Gene targets were additionally 
confirmed using chromatin immunoprecipitation (ChIP) analyses to identify sites in the 
upregulated gene promoters that were associated with E2F1.  Using subtractive 
hybridization, Iwanaga et. al., further demonstrated that genes associated with DNA 
repair, transcription, signal transduction, and cellular metabolism were specifically 
upregulated in response to ectopic E2F1 expression in serum stimulated mouse 
fibroblasts (49).  Altogether, there appears to be a large number of E2F1 genomic targets 
involved in a gamut of cell processes that both stimulate and inhibit cell growth.   
E2F1 has a dual functional nature that appears to maintain balanced cell growth. 
Quiescent fibroblasts simultaneously entered S-phase and underwent p53 dependent 
apoptosis, after the induction of an overexpressing E2F1 plasmid (50).  Although 
abnormal expression of E2F1 appears to initiate a governing mechanism to regulate 
cellular entry into an irregular proliferative state, the induction of cell cycle genes appears 
to overcompensate for the effects of activated apoptotic pathways.  The expression of a 
constitutively active E2F1 protein in rat embryo fibroblasts resulted in the presence of 
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morphologicaly transformed foci (51). E2F1 possibly induces  hyperproliferative states 
by driving cells into S-phase.  E2F1 may upregulate cyclin E to phosphorylate and 
inactivate the pRb checkpoint (52).  Mann et al. demonstrated that the expression of E2F1 
in U2-OS cells (a human osteosarcoma cell line) blocks p16 mediated proliferative arrest 
(53), therefore propelling cells past the  G1/S-phase checkpoint. Several factors are 
required during S-phase to insure correct DNA replication.  DNA methyl transferase 1 
(DNMT1), is a transcriptional E2F1 target (54) that plays a vital role in maintaining 
catalyticaly silenced genes during DNA replication (55).   
 DNMT1 is a member of the DNA methyltransferase family which includes 
DNMT3 (a,b) and DNMTL (as reviewed in (56)).  DNMT3 (a,b) initiates de novo 
methylation (57) that is enhanced by DNMT3L (58) and maintained by DNMT1 (59).  
Full length DNMT1 (1616 amino acids) is the largest of the DNMT family members and 
contains a region within the catalytic domain is highly conserved across DNMT members 
(as reviewed in (60)). Less defined DNMT1 isoforms such as oocyte DNMT1 
(DNMT1o) (-114 AA from N-terminal) (61) and somatic cell expressed DNMT1b (+48 
nucleotides between exon 4 and 5) are cell specific (62).   The DNMT1 structure enables 
interactions at the DNA replication fork that permit the methylation of newly synthesized 
DNA strands.  Once the nuclear localization sequence has directed the enzyme to the 
nucleus, DNMT1 is recruited via the proliferating cell nuclear antigen (PCNA) binding 
domain to PCNA clamps located at the replication foci (63, 64).  Additional DNA 
replication foci localization is mediated by the targeting sequence (65).  At the DNA 
replication fork, the CXXC domain facilitates genomic contacts by penetrating the major 
groove and binding specifically to regions of unmethylated CpG dinucleotides (66) 
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(Figure 1.2).  Two bromo-adjacent homology domains (BAH1 and 2) are located between 
the CXXC and catalytic motifs.  BAH (1 and 2) tether the CXXC domain to the DNA, 
blocking access of the catalytic domain to the unmethylated sites. Certain structural 
confirmations of the BAH motifs additionally retain the target recognition domain in a 
restrictive structural confirmation.  The BAH domains establish a large docking structure 
capable of facilitating protein interactions that may affect DNMT1 activity (66).  
Additionally the N-terminal interacts with histone deacetylase 2 (HDAC2) and contains a 
region capable of recruiting a co-repressor known as DNA methyltransferase associated 
protein 1 (DMAP1) (67).  Methylation ensues once the catalytic domain gains access to 
DNA (66).   
 Methylation is a catalytic means by which DNMT1 modulates gene expression.  
DNMT1 catalyzes the transfer of methyl groups from S-adenosylmethionine to the 
5’carbon of the cytosine ring located in Cytosine-phosphate-Guanine (CpG) 
dinucleotides (as reviewed in (68)).  CpG dinucleotides are occasionally clustered in CpG 
islands (CGI) defined by a set of algorithmic parameters (%GC content  50%; CpG 
dinucleotides obsesrved/expected  0.6; and the CG rich sequence  200bps) (69).  
Under normal circumstances CGIs are predominantly unmethylated. However, increased 
gene promoter hypermethylation within CGIs tends to occur  in certain cancer types (as 
reviewed in (70)).  CGIs as a result, are prone to hypermethylation in environments with 
high DNA methyltransferase activity.  In addition to CGIs, CpG dinucleotides are present 
in currently undefined arrangements that facilitate methylation in cell context dependent 
manners that possibly influence organismal development.  A diverse CpG landscape 
provides a platform for complex DNA methylation profiles that differentially affect the 
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 Figure 1.2 Cartoon representation of DNMT1 interacting with DNA.  Cartoons of 
DNMT1 were created using protein database number 3TPA.  (A) The Zn fingers of the 
CXXC domain are shown interacting with the unmethylated DNA CpG dinucleotides and 
block interaction with the catalytic site.  The target recognition domain and BAH 
domains are additionally depicted in the cartoon.  (B) A theoretical interpretation of 
cytosine methylation by the catalytic domain. 
 
 
12
regulation of gene transcription.  Generally thought to repress transcription, CpG 
methylation within intra- and inter-genic regions were observed in association with 
transcriptionally expressed genes (as reviewed in (71).  Theories continue to evolve 
regarding the functional outcomes of positional CpG dinucleotide methylation.  
Methylated DNA is usually bound by proteins that add another level of 
transcriptional regulation.  The recruitment of functionally different methyl-CpG binding 
protein (MBD) family members (MeCP2 and MBD1-2 and 4) to the DNA, occurs in a 
cell context (species and developmental phase) dependent manner (as reviewed in (72)).  
The MBDs establish various complexes that may repress or induce transcription.  
Methylated DNA binding protein 2 (MeCP2) recognizes symmetrical methylation and 
facilitates repression through the compaction of the nucleosome (73).  Conversely, a 
study, using a neuronal cell line, showed that 63% of the genomic promoters bound by 
MeCP2 were transcriptionally active (74). MBDs deacetylate histones by recruiting 
multi-subunit complexes. MBD2 and MBD3 were shown to respectively interact with 
NuRD and MeCP1 complexes that contain active histone deacetylases (75, 76) (Figure 
1.3).  The multilayered regulation of methylated DNA seems to support a fluid regulatory 
system that allows for flexible transitions between expressional programs.   
Abnormal levels of methylation potentially promote oncogenesis.  Although the 
hypermethylation of promoter CGIs occur naturally, tumor suppressor gene 
hypermethylation is observed more frequently in certain cancers (P16
INK4A
 in solid 
lymphomas, BRCA1 in non-inherited breast cancer, and hMLH1 in MIN+ cancers) (as 
reviewed in (77).  Hypomethylation assessed on a global genomic level was associated 
with  hepatocellular and cervical cancers and breast ductal carcinomas ((as reviewed in 
13
 Figure 1.3 Methylation driven chromatin compaction.  Bead-like units represent 
nucleosomes that are composed of eight histones.  The nucleosomes are wrapped with 
DNA that has either methylated or unmethylated cytosines, respectively represented by a 
filled or open circle.  Methyl binding protein 2 (MBD2) facilitates heterochromatin 
formation through interactions with MeCP1 and the NuRD complex to deacetylate 
histone tails.  Acetyl groups are represented by “Ac”. 
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(78)).  Genomic hypermethylation may result from abnormal increases in DNMT1 
expression.  Induced overexpression of DNMT1 in a transgenic mouse resulted in the 
hypermethylation of a region located on the imprinted Igf2 allele (79).  Binding of all the 
accessible CpG sites potentially occurs in the presence of elevated DNMT1 levels.  The 
over abundant enzyme may seek available CpG sites and promote de novo methylation in 
an additional subset of genes. DNMT1 was shown to methylate nucleasomal DNA in a 
cell free based system (80).  De novo methylation appears to be reliant on DNMT1 over 
expression and is CGI specific (81, 82). Although much focus has been placed on the 
catalytic function of DNMT1, the enzyme is observed to mediate methylation 
independent gene regulation. 
The DNMT1 structure enables both known and potential protein interactions that 
may facilitate the regulation of targeted genes in a catalytically independent manner.  
Rountree et. al. demonstrated that a catalytically absent N-terminal region of DNMT1 
was capable of repression  through interactions with either HDAC2 or the  DMAP1 co-
repressor mentioned earlier (67).  Another study also identified a homologus trithorax 
related protein HRX repressive domain upstream of the catalytic region capable of 
silencing transcription through active HDAC1 interactions (83).  In addition to known 
domain interactions which facilitate methylation independent repression, the ability of 
DNMT1 to complex with known histone modifiers (HP1, G9a, and EZH2) may provide 
an alternate route for genetic regulation (as further discussed in chapter 2).  DNMT1 as a 
result, is capable of dynamically modulating gene expression.   
 DNMT1 is responsible for maintaining appropriate cellular proliferation and 
development.  Loss of DNMT1 function in homozygous mutant mice led to disruptions 
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of genomic imprints and resulted in embryonic death (84, 85).  The requirement for 
DNMT1 in embryonic development suggests that the protein plays an essential role in 
cellular differentiation.  DNMT1 downregulation induced epidermal progenitors to 
differentiate by abrogating self-renewing mechanisms (86).  The protein also functions to 
limit replication errors during S-phase. In the presence of reduced DNMT1 levels, 
mismatch repair mechanisms are compromised and allow for the accumulation of 
mutations (87).  While abnormally low expression of DNMT1 disrupts certain cellular 
processes, elevated levels tend to confer oncogenic properties. DNMT1 overexpression is 
associated with many cancers (88-91) and transforms NIH 3T3 mouse fibroblasts into 
cells capable of initiating xenograft tumors (92).  DNMT1 as described maintains a 
delicate balance between proliferation and differentiation.      
 E2F1 and DNMT1 function to regulate the cell cycle and thus control a vital 
aspect of cellular proliferation.  Abnormalities in either E2F1 or DNMT1 have severe 
consequences for both cellular differentiation and tumorigenesis. E2F1 may illicit 
transformative responses through the activation of and cooperation with DNMT1.      
 
Castration Resistant Prostate Cancer 
Although the mechanisms of prostate cancer progression are unclear, treatment options 
are much more optimistic for properly diagnosed lower stage cancers compared to 
advanced disease.  In the 1940s, advanced prostate cancer was characterized as a 
hormone dependent carcinoma (93).  Subsequent studies led to hormonal ablation 
treatments that seemed to cure patients by increasing wellness and decreasing tumor size.  
The short lived effects were met with the recurrence of an aggressive hormone 
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independent cancer, currently known as castration resistant prostate cancer (CRPC) (as 
reviewed in (94)). Many have tried to uncover the molecular events involved in the onset 
of the hormone insensitive disease using currently available models of CRPC. 
CRPC models have been developed from prostate cancer cell lines and the 
manipulation of current genetic murine models such as Transgenic Adenocarcinoma of 
the Mouse Prostate (TRAMP).  Cell lines derived from pre-existing CRPC metastes (R 
3327 MAT LyLu, PC-3,TsuPr1) (95-97) maintain androgen insensitive characteristics, 
while other prostate lines have been modified to acquire castration resistant properties 
(LNCaP C88 and LNCaP C4-2) (98, 99) (Table 1.1).  Androgen independence is clearly 
evident in many cell lines. However, cells in culture have a limited ability to recapitulate 
human disease.  Cells lines have altered molecular profiles in the absence of niche 
specific paracrine signals. While functional studies may become constrained by the 
features of the cell culturing environment, human tissue studies may further corroborate 
mechanistic findings.  Animal models (castrated TRAMP, cre floxed Pten, and 
Pten/Nkx3.1 KO) (100-104) represent the standard of murine models available for the 
interrogation of niche specific cellular mechanisms in vivo.  The emergence of CRPC was 
first observed in castrated TRAMP mice, although, TRAMP tumors rarely metastasize to 
the bone and show a predominantly neuroendocrine phenotype (105, 106).  Both prostate 
cancer progression and CRPC were observed in Pten/NKx3.1 double knockouts and 
prostate specific cre floxed Pten mice.  While Pten/NKx3.1 double knockout mice better 
recapitulated the bone metastasis observed in human cancer, the floxed Pten model show 
inconsistent bone met rates. The present models are variable and may simulate subtypes 
of CRPC. 
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A number of pathways are associated with CRPC progression.  Both increased 
AR expression and high PSA secretion during the emergence of CRPC (107, 108) 
suggested an oncogenic role for an active androgen independent AR. Studies have mainly 
focused on AR abnormalities (mutation, co-activation, growth factor stimulation, and 
amplification) that permit the unregulated induction of growth promoting genes in the 
absence of androgens (as reviewed in (109)).  Studies continue to explore the AR 
independent pathways that support CRPC tumor progression.  Marques et. al., using a 
castration induced cell line, identified significant expressional abnormalities in a subset 
of genes (TWIST1, VAV3, and DKK3) associated with alternate proliferative pathways 
(110).  Neuroendocrine cells present during CRPC may also secrete growth promoting 
peptides, while the loss of Pten potentially increases bcl2 and inhibits apoptosis (as 
reviewed in (111)). An additional feature of CRPC to consider, is the significant decrease 
in AR expression during cancer progression studies (112, 113).  We further explore the 
regulatory factors that facilitate AR repression utilizing a castrated TRAMP model of 
CRPC in chapter 3.  Normal terminally differentiated prostate luminal epithelial cells 
depend on AR to transcriptionally activate programs that inhibit proliferation.  These 
studies suggest that tumorigenic cells may repress normal functioning AR to maintain a 
high proliferative potential during CRPC.   
Our work sought to define a specific molecular axis involved in AR repression 
and to evaluate a potential role for the AR regulatory mechanism during CRPC.  The 
hyperproliferative nature of AR negative T/A cells led us to consider new roles that cell 
cycle regulators have in regulating AR expression.  The S-phase inducing E2F1 
transcription factor exhibits the ability to drive cells into the cell cycle and target the 
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transcription of DNMT1, a potent epigenetic silencer that is associated with cellular 
proliferation.  We hypothesized that AR repression is mediated by an E2F1/DNMT1 axis 
within proliferative cells that are AR negative.  
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CHAPTER II 
 
REPRESSION OF ANDROGEN RECEPTOR TRANSCRIPTION THROUGH THE 
E2F1/DNMT1 AXIS 
 
ABSTRACT 
Although androgen receptor (AR) function has been extensively studied, regulation of the 
AR gene itself has been much less characterized.  In this study, we observed a dramatic 
reduction in the expression of androgen receptor mRNA and protein in hyperproliferative 
prostate epithelium of keratin 5 promoter driven E2F1 transgenic mice.  To confirm an 
inhibitory function for E2F1 on AR transcription, we showed that E2F1 inhibited the 
transcription of endogenous AR mRNA, subsequent AR protein, and AR promoter 
activity in both human and mouse epithelial cells.  E2F1 also inhibited androgen-
stimulated activation of two AR target gene promoters.  To elucidate the molecular 
mechanism of E2F-mediated inhibition of AR, we evaluated the effects of two functional 
E2F1 mutants on AR promoter activity, and found that the transactivation domain 
appears to mediate E2F1 repression of the AR promoter.  Because DNMT1 is a 
downstream target of E2F1, we examined DNMT1 function in AR repression.  
Repression of endogenous AR in normal human prostate epithelial cells was relieved by 
DNMT1 knock down.  DNMT1 was shown to be physically associated within the AR 
minimal promoter located 22 bps from the transcription start site, however, 
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methylation remained unchanged at the promoter regardless of DNMT1 expression. 
Taken together, our results suggest that DNMT1 operates either as a functional 
intermediary or in cooperation with E2F1 to inhibit AR gene expression in a methylation 
independent manner.   
 
INTRODUCTION 
Androgens are required for prostate gland development and for prostatic function and 
glandular maintenance in the adult male (1). Androgen action is mediated through the 
androgen receptor (AR), a ligand-activated nuclear transcription factor. AR expression is 
found in a variety of tissues, including prostate and breast, and changes throughout 
development, aging and malignant transformation (reviewed in (2)).  AR exists in the 
cytoplasm and is associated with at least three heat shock proteins, hsp56, hsp70 and 
hsp90 (3).  Upon androgen binding and activation of the AR, heat shock proteins 
dissociate and expose the nuclear localization domain which directs the receptor to the 
nucleus (4).  Prior to nuclear translocation, the androgen/AR complex undergoes 
dimerization and phosphorylation.  Upon entering the nucleus, the AR binds to androgen 
response elements (ARE) in the promoter or enhancer region of numerous androgen-
responsive genes.  Several AR co-activators have been identified (ARA 70, ARA 55 and 
ARA 54) which also interact with and regulate AR gene transactivation (5, 6).  Thus, 
ligand-activated AR may stimulate androgen-regulated genes through a variety of 
mechanisms. AR function and the signaling pathways regulated through androgen and 
AR interaction have been extensively studied for decades however; regulation of the AR 
gene itself is not clearly understood. 
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 Studies have shown that transcriptional regulation of AR is cell specific and age-
dependent (7, 8).  The promoter region of the AR gene lacks transcriptional regulatory 
sequences (TATA and CAAT), but is rich in GC sequences (9, 10).  There are at least 
two transcription initiation start sites whose use vary depending on cell type (11).  
Studies of the AR promoter have identified potential binding sites for several 
transcription factors, however, there have only been a few well characterized studies 
demonstrating transcriptional regulation of AR.  For example, Sp1 (9, 11) has been 
shown to be a positive regulator of AR gene expression, whereas, NF- B p50/p50 and 
NF-1 have been shown to be strong negative regulators of AR (12, 13).  The mechanisms 
underlying the repression of the AR gene remain to be elucidated.  
The E2F family of transcription factors control cell proliferation by regulating cell 
cycle progression (14-16). The E2F family has eight characterized family members 
(E2F1-E2F8) which can form heterodimers with DP family members (DP1, 2, and 3), 
giving rise to functional E2F activity (16).  E2Fs control entry into the cell cycle and 
regulate G1/S phase transition by regulating the transcription of genes that encode cell 
cycle regulatory proteins including Cyclin E, Cyclin A, Cdc 2, Cdc 25A, and 
proliferating nuclear cell antigen (PCNA), as well as enzymes involved in nucleotide 
biosynthesis such as dihydrofolate reductase, thymidylate synthase and thymidine kinase 
(17).  E2F1, E2F2 and E2F3 are traditionally thought of as transcriptional activators of 
E2F responsive genes, whereas E2F4, E2F5, E2F6, E2F7, and E2F8 act as transcriptional 
repressors. Overexpression of E2Fs 1-3 in serum starved cells induces S-phase entry and 
DNA synthesis by binding to DNA response elements and activating the transcription of 
E2F target genes (17-19).  E2Fs 1-3 can also override growth-arrest signals induced by 
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Cdk inhibitors p16 (19) and can act as both oncogenes and tumor suppressors (20-22). 
E2F1 binding sites have been reported in the promoters of the breast cancer susceptibility 
gene BRCA1 (23), p73 (24, 25), the tumor suppressor gene p14
ARF
 (26), and the gene for 
apoptosis protease-activating factor 1 (Apaf-1) (27).   We have identified E2F binding 
sites in the promoter of DNA methyltransferase 1 (DNMT1) that allow for regulation by 
E2F1 (28).  E2F1 has also been shown to act as a direct transcriptional repressor for 
several genes including urokinase-type PA (uPA) (29), the anti-apoptotic protein Mcl-1 
(30), and human telomerase reverse transcriptase (31).  These results suggest that E2F1 
can have both positive and negative regulatory roles on gene transcription, however the 
molecular basis of these disparate functions is not known.   
The DNA methyltransferases (DNMT 1, 3a, 3b and 3L) play an integral role in 
the epigenetic regulation of many genes.  All DNMTs except for 3L have a catalytic 
domain that facilitates the transfer of methyl groups from S-adenosyl-methionine to 
cytosines located in CG dinucleotides.  DNMT 3a and 3b are generally responsible for 
genome-wide de novo methylation during early embryogenesis (32).  DNMT3a is shown 
to methylate both maternally and paternally imprinted genes in germ-line cells (33), 
while DNMT3b maintains the chromosomal stability of 6, 9, and 16 via centromeric 
methylation (34).  Genomic methylation by DNMT3 (a and b) is enhanced in the 
presence of DNMT3L (35).  Initial methylation by the DNMT3 family members is 
maintained by DNMT1, which has an affinity for hemimethylated DNA during 
replication and cell division.  DNMT1 is necessary for mouse fetal development and the 
progenitor and self-renewing characteristics of somatic cells located in the epidermis 
(36).  As mentioned, DNMT1 was characterized in our lab to be a direct transcriptional 
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target of E2F1 (28) and may mediate targeted repression by E2F1. Previous work in our 
lab has additionally shown that the DNMT1 is trans-activated by  
In this study, we explored a regulatory mechanism that controls the endogenous 
expression of AR in prostate epithelium.  We investigated the effects of the transcription 
factor E2F1 on AR mRNA and protein expression in both human and mouse prostate 
epithelial cells.  We demonstrate how E2F-1, a classical transcriptional activator, might 
cooperate with DNMT1 to repress AR transcription in the prostate gland.   
 
MATERIALS AND METHODS  
 
Cell Culture.  LNCaP and DU145 cell lines obtained from American Type Culture 
Collection, Rockville, MD and BPH-1 cells received from Dr. Simon Hayward, 
Vanderbilt University Medical Center (37) were cultured in RPMI 1640 medium 
supplemented with 8% fetal bovine serum (FBS), 0.1% penicillin/streptomycin and 0.1% 
L-glutamine.  Human prostate epithelial cells (hPrEC) purchased from Lonza/Clonetics, 
Walkersville, MD were maintained in Prostate Epithelial Cell Growth Medium 
(Lonza/Clonetics).  Mouse prostate epithelial (PrE) cells, previously described in 
reference (38) were cultured in RPMI 1640 medium supplemented with 5% fetal bovine 
serum (FBS), 0.1% penicillin/streptomycin and 0.1% L-glutamine.   
For the development of the PrE-E2F1 stable cell lines, PrE cells were transfected 
with pcDNA3-E2F1 (kindly provided by W. Kaelin, (39) or empty vector pcDNA3 
(Invitrogen, Carlsbad, CA) using Tfx50 (Promega, Madison, WI) according to the 
manufacturer’s protocol.  Stable clones were selected in RPMI 1640 media containing 
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5% FBS, 0.1 % penicillin/streptomycin, 0.1% L-glutamine and 200 g/ml G418 (Sigma, 
St. Louis, MO).  For the development of the DNMT1 knock-down stable BPH-1 and 
transient hPrEC cell lines, cells were lentivirally infected with a pLKO.1-puro vector 
either expressing DNMT1 specific short hairpin RNA (shRNA) (clone ID: 
NM_001379.1-1687s1c1), non-targeting shRNA (Cat#: SHC002) or no shRNA insert 
(Sigma/Mission, St. Louis, MO). Stable shRNA BPH-1 clones were selected in RPMI 
1640 media containing 8% FBS, 0.1 % penicillin/streptomycin, 0.1% L-glutamine and 1 
g/ml puromycin (Sigma, St. Louis, MO). 
 
Cell treatments.  All synthentic androgen (R1881) treatments were done at 10
-9
M for 24h 
after 15h of serum starvation.  All 5-aza-2’-deoxycytidine (5Aza) (Sigma) treatments 
were done in either complete culturing media used for DU145 or hPrEc lines.  Fresh 
media containing 1 M 5Aza was added every 24h for a total of 72h and DMSO 
treatments were matched as vehicle controls. 
   
Northern Blot Analysis.  Total RNA was prepared using QIAGEN RNA Easy kit per 
manufacturer’s protocol (QIAGEN, Valencia, CA).  Twenty micrograms of RNA was 
resolved by gel electrophoresis under denaturing conditions and RNA was transferred to 
a Duralon-UV membrane (STRATAGENE, La Jolla, CA) overnight by capillary action 
in 20 X SSC buffer (3 M NaCl and 0.3 M Na Citrate).  RNA was crosslinked to the 
membrane by UV cross linking.  A 1.6 kb human AR cDNA fragment was isolated from 
CMV3-hAR3.1 (kindly provided by D. Robins, University of Michigan, Ann Arbor, MI) 
using a HindIII and NheI restriction enzyme sites. A 1.5 mouse AR cDNA fragment was 
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isolated from CMV5-mAR (kindly provided by D. Robins, University of Michigan, Ann 
Arbor, MI) using HindIII restriction enzyme sites.  The human and mouse AR cDNA 
fragments were gel purified using QIAGEN Gel Purification Kit, per manufacturer’s 
protocol and subsequently labeled with [ -
32
P] dATP using the random oligonucleotide-
primer labeling kit (STRATAGENE) and purified on STRATAGNE Nucleotide Push 
Columns following manufacturer’s protocol.  The [ -32P] dATP labeled probes were 
hybridized to a Duralon-UV membrane (STRATAGENE) at 65
o
C overnight in 
hybridization buffer (0.25 M Na2HPO4, pH 7.2 and 7% SDS) while rotating.  The 
membrane was subsequently washed twice for 45 min each in 20 mM Na2HPO4, pH 7.2 
and 5% SDS followed by two additional washes for 45 min each in 20 mM Na2HPO4, pH 
7.2 and 1 % SDS.    The membranes were exposed to X-ray film (Kodak, Rochester, NY) 
overnight and visualized by autoradiography. 
 
Western Blot Analysis.  Cells were either trypsinized, centrifuged and washed one time 
with PBS then lysed with RIPA buffer (50 mM Tris pH 8.0, 120 mM NaCl, 0.5% 
Nonidet P40, 1.0 mM EGTA, 200 g/ml PMSF, 50 g/ml aprotinin, 5 g/ml leupeptin, 
200 M sodium orthovanidate) or lysed directly in the plate.  The hPrEC lines were 
harevested 4 days post infection, while stably infected BPH-1 cells were collected 4 days 
post selection in puromycin (1 g/ml).  Protein concentrations were determined using 
Bradford Protein Assay Reagent (BIO-RAD, Hercules, CA), following manufacturer’s 
protocol.  For Western blot analysis, protein extract was subjected to gel electrophoresis 
either on a tris-glycine polyacrylamide gel (Invitrogen) (LNCaP and mPrE) or on a Nu 
Page tris-acetate polyacrylamide gel (Invitrogen) (BPH-1 and hPrEC).  The gel was 
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transferred to Optitran nitrocellulose membrane (Schleicher & Schuell Biosciences Inc. 
Keene, NH) by electrophoresis for 1 hour at 45 V.  The membrane was blocked in 10% 
nonfat dry milk in TBST (10 mM Tris, 250 mM NaCl, 1% Tween 20) for 1 hour at room 
temperature and immunoblotted with primary antibodies for AR (N-20, Santa Cruz, Santa 
Cruz, CA), E2F1 (KH-95, Pharmingen, Franklin Lakes, NJ), Rb (Pharmingen), PCNA 
(C-20, Santa Cruz), E-Cadherin (H-108 Santa Cruz), Cyclin E (M-20, Santa Cruz), 
DNMT1 (Raw M0231S prep gift from Dr. Sriharsa Pradhan, New England BioLabs Inc., 
Ipswich, MA), -actin (C-11, Santa Cruz), or actin (AC-40 Sigma, St. Louis, MO).   The 
membrane was incubated with secondary antibody conjugated to horseradish peroxidase 
(BIO-RAD, Hercules, CA) and the bands were detected using ECL (PIERCE, Rockford, 
IL) detection system, following manufacturer’s protocol. 
 
Luciferase Assay.  LNCaP and PrE cells were plated at 2 x 10
5
 cells per 6 well dish and 
incubated at 37
o
C overnight.  Stably infected BPH-1s with DNMT1 shRNAs were plated 
at a 1 to 60 passage into a 12 well dish and incubated at 37
o
C overnight.  Cells were co-
transfected with 1 g/ml of either of the following promoter-luciferase reporter 
constructs; DHFR-Luc, E2F-Luc and CRE-Luc were kindly provided by G. Denis, 
Boston University, Boston, MA (40), 2.0 kb human AR promoter-Luc (hAR-Luc) (kindly 
provided by F. H. Sarkar, Wayne State University, Detroit, MI), 1.5 kb mouse AR 
promoter-Luc (mAR-Luc) was kindly provided by D. J. Tindall, Mayo Clinic, Rochester, 
MN (41), MMTV-Luc (gift from E. Keller, University of Michigan, Ann Arbor, MI) and 
3XHRE-Luc (gift from D. Robins, University of Michigan, Ann Arbor, MI).  The 
promoter-reporter constructs were co-transfected in LNCaP and PrE cells with either 
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empty pcDNA3 vector, wild type E2F1 or the following E2F1 mutants (E2F1-284, or 
Eco132) (gifts from W.D. Cress, Moffitt Cancer Center, Tampa, FL, (30, 42)), a 
dominant negative E2F1 was kindly provided by W. Kaelin, Harvard University, Boston, 
MA, (43) or Tag (gift from M. Imperiale, University of Michigan, Ann Arbor MI).  The 
pSV-beta-galactosidase ( -gal, Promega) expression plasmid was co-transfected into 
LNCAP and PrE cell lines at 0.1 g/ml and into hPrEC and BPH-1 cells at 1 g/ml as an 
internal control.  DNA was transfected using Tfx50 transfection reagent (Promega) at a 
ratio of ~3:1 (Tfx50: DNA) following manufacturer’s protocol.  After 72 hours of 
transfection, whole cell lysates were collected in lysis buffer.  Luciferase expression was 
determined by adding 50 l luciferase substrate (Promega) to 50 l of lysate and 
luciferase was monitored using a Monolight 2010 luminometer.  -gal expression was 
monitored using -gal Detection System (Tropix, Bedford, MA) following 
manufacturer’s protocol using Monolight 2010 luminometer.  Samples were assayed in 
triplicate and luciferase activity was normalized to -gal activity. 
 
qRTPCR and PCR Analysis.  Total RNA was extracted by scraping and collecting cells in 
TRizol (Invitrogen, Carlsbad, CA) (1ml per 60mm dish).  The lysate was added at 1ml to 
a pre-spun 2ml heavy phase lock gel tube (5 PRIME Inc., Gaithersburg, MD), incubated 
for 5min at room temperature, and combined with chloroform.  After the mixture was 
centrifuged at 12,000xg for 10min at 4
o
C, the resulting aqueous mixture above the wax 
plug was removed and mixed together with 500 l of isopropanol, and incubated for 10 
min at room temperature.  The mixture was centrifuged into a pellet at 12,000xg for 
10min at 4
o
C and washed 1 time in 70% ethanol.  RNA was reconstituted in 35 l of 
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UltraPure Distilled Water (Invitrgen/GiBCO, Carlsbad, CA) and quantitated with the 
NanoDrop Spectrophotometer ND-1000 (Thermoscientific, Wilmington, DE), treated 
with DNase I (Invitrogen), then converted to cDNA using the Thermoscript RT PCR 
Reaction System (Invitrogen) according to the manufacture’s protocol.  The qRTPCR 
was conducted with the following primers:  
 
human AR forward: 5’-GACCAGATGGCTGTCATTCA-3’ 
human AR reverse: 5’-GGAGCCATCCAAACTCTTGA-3’ 
 
human GAPDH forward: 5’-TGCACCACCAACTGCTTAGC-3’ 
human GAPDH reverse: 5’-GGCATGGACTGTGGTCATGAG-3’ 
 
A Mastercycler ep realpex
2
 (eppendorf, Hamburg, Germany) using SYBR green PCR 
Master Mix (Applied Biosystems, Carlsbad, CA) was used to amplify the cDNA with the 
following PCR conditions; denatured at 95
o
C for 3min and subjected to 40 cycles (95
o
C 
30 sec, 60
o
C 30sec, and 72
o
C 30sec).  The primers were used in a separate PCR and 
electrophoresed on a gel to verify the presence of a single amplicon from the cDNA. 
Each sample reaction in the qRTPCR was done in triplicate in a 96 well plate format.  
Cycle threshold units were obtained using Mastercycler ep realpex
2
 software.  Data was 
analyzed using the 2
- CT
 method (44) relative to GAPDH values.  PCR was conducted 
on cDNA using the human AR and GAPDH primers referred to above in combination 
with platinum PCR super mix (Invitrogen).   Reactions were run in an epindorf 
thermocycler denatured at 95
o
C for 3min, subjected to 35 cycles (95
o
C 30 sec, 60
o
C 
30sec, and 72
o
C 30sec) and processed on a 2% agarose gel.   
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Chromatin Immunoprecipitation qPCR Analysis.  For each ChIP 1X10
7
 BPH-1 cells were 
cross-linked with 1% formaldehyde for 10 min at room temperature on a rocking 
platform.  The reaction was quenched with 0.125 M glycine.  Cells were scraped and 
collected in cold PBS containing protease inhibitors (200 ug/ml PMSF, 50 ug/ml 
aprotinin, 5 ug/ml leupeptin, and 200 uM sodium orthovanidate), following 2 washes in 
cold PBS. The harvested cells were pelleted at 5,000 rpm for 6 min at 4
o
C and washed 
once with cold PBS containing protease inhibitors.  Lysates were prepared using the 
reagents in the Magna ChIP A kit (Millipore, Temecula, CA) according to manufacture 
instructions, however, the lysis buffer available was substituted with 400ul of SDS lysis 
buffer (Millipore) containing kit supplied protease inhibitors. The chromatin in the lysate 
was sheared to ≤ 600bps in a 2ml tube placed in a Covaris S2 (Covaris Inc., Woburn, 
MA) water bath set to the following cavitation parameters: duty cycle, 20%; intensity, 5; 
cycles per burst, 200; cycle time, 30 sec; and cycles, 30.  The sheared chromatin was 
processed and immunoprecipitated with 5 g of either DNMT1 (ab19505, abcam, 
Cambridge, MA) or rabbit IgG (sc-2027, Santa Cruz) using the reagents and instructions 
provided in the Magna ChIP A kit.  The purified ChIP DNA was retrieved with 40 l of 
elution buffer C.  The DNA sample was amplified with a two step PCR program 
(Denaturation at 95
o
C for 10min and 40 cycles of 95
o
C for 15 sec and 60
o
C for 1 min) 
using SYBR green PCR Master Mix in a StepOnePlus Real-Time PCR thermocycler 
(Applied Biosystems) employing the following primers: 
 
site A forward: 5’-GACTCGCAAACTGTTGCATT-3’ 
site A reverse: 5’-TACAGCACTGGAGCGGCTA-3’ 
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site B forward: 5’-CCTAGCAGGGCAGATCTTGT-3’ 
site B reverse: 5’-TCCCCTTCTCTTGCTCAGAA-3’ 
 
site C forward: 5’-GGTAGGAAGTGGCTGAATTCTGGATGA-3’ 
site C reverse: 5’-CCCTGCCCATGCACCTGCTC-3’ 
 
human PS2 forward: 5’-TTCCGGCCATCTCTCACTAT-3’ 
human PS2 reverse: 5’-CGGGGATCCTCTGAGACA-3’ 
 
human ABCB1 forward: 5’-TCTAGAGAGGTGCAACGGAAGCCA-3’ 
human ABCB1 reverse: 5’-CCTGCCCAGCCAATCAGCCT-3’ 
 
An extended program (95
o
C for 15min, 60
o
C for 1min, and 95
o
C for 15 sec) was 
used to create a melting curve that was analyzed with the StepOne software v2.1 package 
to verify that the primers only amplify a single amplicon from genomic DNA. Each 
sample reaction in the qPCR was done in triplicate in a 96 well plate format.  Cycle 
threshold units were obtained using StepOne software v2.1.  Data is represented as a 
percent of input using a derivation of the 2
- CT
 method (44). 
 
Bisulfite sequencing.  Genomic DNA (gDNA) was extracted from cells using the Wizard 
Genomic DNA Purification kit (Promega) and quantified with the NanoDrop 
Spectrophotometer ND-1000 (Thermoscientific, Wilmington, DE) .  A 250 ng sample of 
DNA was bisulfite converted using the EZ DNA Methylation-Direct kit (Zymo Research, 
Orange, CA) according to the instructions provided by the manufacturer.  The following 
bisulfite converted DNA specific primers, targeting a region in the AR (NM_000044) 
minimal promoter were created with Methyl Primer Express v1.0: 
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bisulfite sequence forward: 5’-GGGAGTTAGTTTGTTGGGAG-3’ 
bisulfite sequence reverse: 5’-TCCTACCAAACACTTTCCTTACT-3’ 
Amplification of the bisulfite converted gDNA was accomplished using special ZymoTaq 
PreMix (Zymo Research) polymerase to facilitate the production of aplicons with A 
overhangs using the following PCR program: denature at 95
o
C for 10 minutes, run 35 
cycles (95
o
C 30 sec, 59
o
C 30 sec, and 72
o
C 60 sec), run a final extension at72
o
C for 7 
min, and hold at 4
o
C.  PCR product was combined with pCR8/GW/TOPO TA cloning 
vector (Invitrogen) in a mixture prescribed by the manufacture to facilitate the insertion 
of the amplified products into the plasmids which contain sequencing primer sites that 
flank the insert.  Plasmids were transformed and plated in One Shot Top 10 chemically 
competent cells (Invitrogen) per manufacturer’s instructions and at least 12 bacterial 
colonies were individually grown in 5ml of LB containing spectinomycin (100 g/ml). 
Plasmids were harvested from the bacteria using the Wizard Plus SV Miniprep kit 
(Promega) and sequenced with the M13 forward and reverse primers at the University of 
Michigan DNA sequencing core.    
 
Statistics- Data showing significance was analyzed using 2-tailed Student’s t test.  P < 
0.05 was accepted as the level of significance. 
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RESULTS 
 
Transgenic K5-E2F1 prostate glands exhibit hyper-proliferative epithelium and an 
atypical morphology.  Accumulating evidence suggests that increased E2F1 activity 
reactivates several aspects of benign and malignant disease including increases in cellular 
proliferation (45, 46). We were curious as to the role of E2F1 in prostate gland disease 
processes.  We have shown previously that normal human prostate gland expresses low 
levels of E2F1 (47). We were thus intrigued by the observation that keratin 5 promoter 
driven expression of the human E2F1 gene in the mouse prostate gland (48), resulted in 
hyperproliferative changes that were not detected in wild type mice (Figure 2.1A). This 
K5 promoter fragment is known to direct transgene expression to the basal cell 
compartment of stratified epithelia of several glandular tissues such a mammary gland, 
salivary gland and prostate (48, 49).  In K5-E2F1 transgenic mice, the majority of glands 
appeared grossly normal and were lined with a single layer of epithelial cells, however 
there were focal areas of increased epithelial hyperplasia with abnormal gland 
architecture in the dorsolateral lobe of the prostate (Figure 2.1A). Some glands had 
increased stratification of epithelial cells that formed compact glands with a cribriform 
growth pattern, representative of prostatic intraepithelial neoplasia (PIN) and some 
nuclear atypia.  Similar lesions were not detected in wild type animals.  Prostate tissue 
from age and strain-matched wild type mice consisted of normal prostatic ducts lined 
with a single layer of epithelial cells surrounded by a thin layer of stroma (Figure 2.1A). 
To further define a role for E2F1 in prostate epithelial cell growth, we generated prostate 
epithelial cells lines from glands harvested from two wild type mice and three K5-E2F1 
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transgenic mice.  Semi-quantitative RT-PCR analysis using specific primers for mouse 
and human E2F1 show the presence of endogenous mouse E2F1 in wild type and K5-
E2F1 cells, however, human E2F1 was only detected in K5-E2F1 cell lines (data not 
shown). In agreement with the hyper-proliferative epithelial histology, the K5-E2F1 lines 
exhibited a 2-fold increase in proliferation compared to wild type cells (Figure 2.1C). We 
also observed a significant reduction of K5-E2F1 cells in G1 phase and a concurrent 
increase in the distribution of cells in G2/M and S phase (data not shown). Western blot 
analysis reflected E2F1 expression and revealed a significant increase in human E2F1 
protein expression in all three K5-E2F1 transgenic lines compared to wild type controls 
(Figure 2.1B). To investigate the molecular events associated with increased E2F1 
expression, we analyzed several regulators of prostate epithelium in addition to E2F1 
target genes.  Whole cell lysates prepared from log phase wild type and K5-E2F1 cells 
were analyzed for Cyclin E and PCNA protein levels.  K5-E2F1 cells exhibited an 
aproximate 3 fold increase in Cyclin E and a 2 fold increase in PCNA (Figure 2.1B).  
Cyclin E and PCNA are E2F1 target genes that regulate DNA synthesis and promote 
G1/S transition, suggesting that E2F can control both DNA replication and mitotic 
activities in our transgenic prostate model and cell lines (50, 51).  The prostate epithelial 
lineage of these cell lines was verified by the expression of the epithelial cell marker E-
cadherin (Figure 2.1B) and the steroid hormone receptors estrogen receptor-beta (ER- ) 
(data not shown). Surprisingly, all 3 K5-E2F1 lines exhibited significant repression of 
AR protein compared to the wild type cells (Figure 2.1B).  An unknown protein is 
additionally observed in the developed western blot for the  K5-E2F1-2 line to run about 
20 kDa lower than full length AR.  The transgenic line may express the AR-A isoform, 
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 Figure 2.1 E2F1 leads to atypical prostatic morphology and increases prostate 
epithelial proliferation in a K5-E2F1 transgenic mouse.  (A)  Histology of prostate 
tissue taken from both K5-E2F1 transgenic and wild type mice.  (B) Prostate epithelial 
cell lines established from both transgenic and wild type mice were analyzed by western 
blot for the expression of E2F1, cell cycle genes (Cyclin E and PCNA), the epithelial cell 
specific marker E-cadherin (E-cad), and Androgen Receptor (AR).  Actin is shown as a 
loading control.  (C) A trypan blue exclusion assay was implemented to measure the 
viability of cell lines obtained from the mouse models.  Each point represents the mean of 
three independent experiments with the standard deviation.   
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characterized by an N-terminal domain that is 187 amino acids (21 kDa) shorter than the 
full length form (52).   
 
E2F1 down regulates AR expression and the promoter activity of AR target genes.  
We were surprised by the reduction in AR expression in the K5-E2F1 transgenic lines 
compared to wildtype lines. To determine if E2F1 directly represses AR transcription, we 
examined whether exogenous expression of E2F1 reduces AR mRNA levels in prostate 
epithelial cells.  Stable E2F1 over-expressing clones were established in mouse prostate 
epithelial cells (PrE) and two clones, PrE2F1-1 and PrE2F1-2, were expanded and 
characterized. Total RNA was harvested and subjected to Northern blot analysis for the 
detection of AR and E2F1 mRNA. Both clones exhibited increased E2F1 mRNA and 
significantly reduced AR mRNA (Figure 2.2A) and protein (Figure 2.2B).  These cells 
exhibited increased E2F activity by exhibiting increased expression of Cyclin E and 
PCNA, two well described E2F-target genes (Figure 2.2B). These result demonstrated 
that exogenous E2F1 is involved in the repression of AR expression.  
The findings from the transgenic animals indicated that E2F1 might be driving a 
proliferative and undifferentiated phenotype. We had previously observed the AR-
regulated prostate specific antigen (PSA) gene was down regulated following E2F1 over 
expression suggesting a repressive activity of E2F1 on AR target genes through the 
repression of AR (47). To explore this possibility, we examined the effect of E2F1 on a 
hormone-responsive promoter/reporter construct (3XHRE-Luc) in the androgen-
responsive prostate cell line, LNCaP.  The 3XHRE-Luc construct has 3 hormone 
response elements cloned in front of a luciferase reporter gene and allows for the 
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 Figure 2.2 Exogenous E2F1 inhibits both AR expression and responsive promoters.  
(A) Northern blot analysis of stably transfected mouse prostate epithelial cells (PrE) with 
either pCDNA3 (control vector) or E2F1 shown as E2F1-1 and E2F1-2 to detect AR and 
E2F1 gene transcription. The 28S and 18S ribosomal bands are shown for loading 
comparison.  (B) Western blot analysis of whole cell lysates harvested from PrE cells 
stably transfected with pcDNA3 (control) or E2F1 for the detection of AR, Cyclin E, and 
PCNA.  β-actin is shown as a loading control.  (A and B) The northern blot and western 
is representative of 3 separate experiments.  LNCaP cells were co-transfected with 1 µg 
of ARE-Luc (C) and 500 ng of either empty pcDNA3 vector or E2F1 in the presence of 
10
-9 
M R1881.  Results were normalized to β-galactosidase (B-gal) from a co-transfected 
CMV promoter driven B-gal reporter construct. The histogram represents the mean value 
of three independent experiments with the indicated standard deviation. The western 
depicts the expression levels for E2F1 and AR relative to tubulin for the transfection and 
treatment conditions.  * indicates P < 0.05 for the indicated comparison in brackets.   
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monitoring of directed hormone receptor activation.  LNCaP cells were co-transfected 
with the 3XHRE-Luc construct with either pcDNA3 (empty vector) or E2F1.  We treated 
cells with the synthetic androgen R1881 to specifically activate AR and observed activity 
from the 3XHRE-Luc reporter (Figure 2.2C).  Co-transfection of E2F1 both abrogated 
3XHRE-Luc activity in the presence of R1881 and downregulated AR protein expression 
(Figure 2.2C).  These results demonstrate that E2F1 inhibits transcriptional regulation of 
AR target gene promoters by inhibiting AR expression. 
 
Transcriptional repression of AR requires the transcriptional regulatory domain of 
E2F1.  To determine if E2F1 exerts repressive activity directly on the AR promoter, we 
utilized a 1.5 kb (-1571 to +131 bp) mouse AR promoter construct (Figure 2.3A) cloned 
upstream of a luciferase reporter cassette (mAR-Luc).  This plasmid was co-transfected 
into normal mouse prostate epithelial (mPrE) cells with either empty pcDNA3 vector 
(control) or wild type E2F1 along with a CMV promoter-driven -galactosidase (B-gal) 
reporter plasmid as an internal control. Wild type E2F1 reduced mouse AR promoter 
activity 3.5 fold compared to cells transfected with empty pcDNA3 plasmid (Figure 
2.3A).  To assess AR promoter activity resulting from the direct disruption of E2F1 
activity, we used a dominant negative E2F1 (DN E2F1) construct encoding a fusion 
cassette of the E2F1 DNA binding and the Rb pocket domain. This fusion binds to E2F 
consensus regions and blocks endogenous E2F1 activity at E2F1-responsive promoters 
(43), when employed in our system relieved repression of the AR promoter (Figure 
2.3A). As a control, we demonstrated that E2F1 activates an E2F-inducible promoter 
containing 4 adjacent E2F consensus binding sites (E2F-Luc), while the DN E2F1 
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construct repressed promoter activity.  We also demonstrated that E2F1 does not have an 
effect on an unrelated CRE-Luc promoter, which contains 4 adjacent cyclic AMP 
regulatory elements in front of a luciferase reporter construct (Figure 2.3A). We 
demonstrated that exogenous E2F1 repressed AR promoter activity. To assure that 
endogenous E2F1 carried out this repressive activity, we disrupted the inhibitory effect of 
endogenous Rb on E2F1 by co-transfection with SV-40 large T antigen (Tag) and 
assessed AR promoter activity. Ectopic expression of Tag led to 9 fold activation of the 
E2F-Luc promoter, but repressed mAR promoter activity nearly 4 fold (Figure 2.3A). 
These results confirm that E2F1, normally a transcriptional activator, participates in the 
repression of the AR promoter. 
To elucidate the mechanism of E2F-mediated inhibition of AR, we examined the 
effects of two functionally debilitating E2F1 mutants on AR promoter activity.  A 
mutation in the DNA binding domain (Eco 132) failed to significantly relieve E2F-
mediated inhibition (Figure 2.3B).  However, deletion of the transactivation domain of 
E2F1 (E2F1 1-284) abrogated the inhibitory effect of E2F1 on the AR promoter (Figure 
2.3B).  As expected, these E2F1 mutants did not activate the dihydrofolate reductase-
luciferase reporter construct (DHFR-Luc), which is known to require both E2F1 
transactivation and DNA binding domains (Figure 2.3B).  These results indicate that the 
transactivation domain of E2F1 appears to be more essential than the DNA binding 
domain for E2F1 repression of the AR promoter.  This observation prompted us to 
examine co-repressive factors that are involved in the E2F1 mediated repression of AR.  
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 Figure 2.3 The E2F1 transactivation domain is required for AR promoter activity 
repression.  (A) mPrE cells were co-transfected with 1 µg of mARp-Luc, E2F-Luc or 
CRE-Luc luciferase reporter constructs with  0.5 µg of empty vector (pcDNA3), wild 
type E2F1, dominant negative E2F1 (DN E2F1) or SV-40 Large T antigen (Tag).  After 
72 hours, cells were harvested and assayed for luciferase expression.  The results are 
shown as averages of three independent experiments.  Assays were done in triplicate and 
mean values are shown with standard deviation.  The results were normalized to β-
galactosidase (B-gal) expression from a co-transfected CMV promoter driven B-gal 
reporter construct.  (B) LNCaP cells were co-transfected with either 1 µg of hAR-Luc or 
DHFR-Luc and 0.5 µg of either wild type E2F1or E2F11-284 mutant constructs.  The 
histograms represent the mean value of three independent experiments with the indicated 
standard deviation.  Results were normalized to β-galactosidase (B-gal) expression from a 
co-transfected CMV promoter driven by a B-gal reporter construct.  * indicates P < 0.05 
for the indicated comparison in brackets.   
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DNMT1 down regulation relieves AR repression in AR negative cells lines. We have 
previously shown that the DNA methyltransferase 1 (DNMT1) gene, which typically 
functions to maintain the methylation and repression of specific genes, was trans-
activated by E2F1 (28).  Interestingly, DNMT1 was shown to be part of an E2F1 
containing complex that facilitated repression at E2F consensus sites (53).  To determine 
if DNMT1 is involved in E2F1 dependent repression of AR transcription, we assessed 
whether AR expression is relieved in the AR negative defined human primary prostate 
epithelial cells (hPrEC) following DNMT1 shRNA knockdown.  The hPrEC line is a 
model of transit/amplifying cells of the prostate gland and as such lacks markers of 
terminal differentiation such as AR expression (54, 55). These cells allow for the study of 
normal mechanisms that regulate AR expression.  The hPrEC line was subjected to a 
transient transduction with either empty short hairpin RNA (shRNA), vector, non-
targeting shRNA or DNMT1 targeting shRNA (4-1 and 4-2) (Figure 2.4A) and processed 
for both qRTPCR and western blot analysis.  Compared to controls, the expression of the 
DNMT1 shRNA sequence resulted in a significant decrease in DNMT1 expression at 
both the transcriptional (data not shown) and protein level (Figure 2.4A).  AR protein and 
transcription increased in response to decreases in DNMT1 expression, indicating that 
gene repression may also involve DNMT1. To assess the role of DNMT1 on AR 
promoter activity, we cloned a region of the AR gene containing a 2kb human AR 
promoter  upstream of a luciferase reporter (hAR-Luc).  Because primary hPrEC cells 
cannot withstand multiple passages required for stable shRNA transduction, we 
employed the immortalized human prostate epithelial line, BPH1, which still maintain a 
non-transformed phenotype (37).  The hAR-Luc construct along with a CMV promoter-
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 Figure 2.4 DNMT1 downregulation relieves AR Expression.  (A) Primary cultures of 
human prostate epithelial cells (hPrEC) and (B) immortalized benign prostate epithelial 
cells (BPH-1) transduced with either control (shVector (shV) and shNon-targeting (NT)) 
or DNMT1 shRNA constructs.  AR and DNMT1 protein expression relative to actin 
loading control were analyzed by Western blot.  The exposures in (B) were taken from 
different sections of the same blot at the same intensity.  AR transcription was analyzed 
using qRTPCR with readings done in triplicate (graphs A and B).  Mean values are 
represented with standard error bars.  (C) shRNA transduced BPH-1 cells (described in A 
and B) were transfected with the human AR promoter luciferase reporter (hAR-Luc) 
construct.  The histograms represent the mean value of three independent experiments 
with the indicated standard deviation.  Results were normalized to β-galactosidase (B-gal) 
expression from a co-transfected CMV promoter driven B-gal reporter construct.  All 
western blots are representative of 3 separate experimental replicates. 
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driven -galactosidase (B-gal) internal control reporter were co-transfected into BPH-1 
cells that were previously transduced with DNMT1 shRNA targeting constructs (Figure 
2.4B).  DNMT1 shRNA relieved AR promoter activity (measured by increased luciferase 
activity) in BPH-1 cells when compared to controls (Figure 2.4C).  These results suggest 
that DNMT1 contributes to the repression of AR promoter activity in normal prostate 
epithelial cells. 
 
DNMT1 associates with the intronic and minimal promoter regions of the AR gene 
independent of methylation activity.  To understand how DNMT1 functions to 
represses AR expression, we explored the possibility for DNMT1 to physically associate 
with the AR gene.  Chromatin immunoprecipitation sequencing (ChIP-seq) analysis 
indentified both DNMT1 and E2F1 associated regions across the whole hPrEC genome 
(data not shown). H-peak analysis (56, 57) of the data revealed regions in the AR 
genomic structure exhibiting significant DNMT1 and E2F1 co-occupancy (Figure 2.5).  
Considering that DNMT1 has been reported to form complexes that bind to E2F 
responsive promoters, we designed primers flanking specific E2F consensus sequences 
(site A, B, and C) in the AR promoter. Site A and B were located within 1,000 bps of the 
transcription start site, while site C corresponded to a location in the ChIP-seq identified 
region of DNMT1 and E2F1 co-occupancy in the first intron (Figure 2.5A).  Although the 
ChIP-seq demonstrated some E2F1 associations with the AR gene, we focused our ChIP 
analysis on DNMT1 interactions, considering that the region under analysis presented 
with weak E2F consensus sites and that the E2F1 DNA binding domain was not 
necessary for AR promoter repression (Figure 2.3B).  Primers were used to analyze a 
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known binding target of DNMT1 located in the PS2 promoter (58) and a non-related 
DNA sequence located in exon 2 of the ABCB1 gene (59).  Rabbit IgG was used to 
control for any non-specific DNA binding incurred by the antibodies.  Quantitative PCR 
indicates that DNMT1 strongly associates with intronic region showing a ≥ 4-fold over 
enrichment at the ABCB1 genomic region.  DNMT1 demonstrated some association with 
sites A and B in the AR gene, showing slightly increased levels of enrichment over 
ABCB1, that were similar to amplification levels at the PS2 promoter (Figure 2.5B).  
DNMT1, therefore, associates with the 5’ UTR and a region in the first intron of the AR 
gene that has a possible affinity for E2F1.   
DNMT1 is traditionally thought to facilitate the repression of target genes through 
a catalytic process that involves the transfer of methyl groups to cytosines located in CG 
dinucleotides present in the DNA sequence.  Aberrant hyper-methylation of the AR 
promoter has been detected in the AR negative metastatic prostate cancer cell lines DU-
145 and TSU-PR1 (60).  ChIP analysis demonstrated that DNMT1 associated with a 
section of DNA spanning a region (+44 to +54) of heavy methylation conserved between 
DU145s and other transformed AR lacking cell lines (61).  To determine whether 
methylation of the AR minimal promoter associated region (Figure 2.5A) is dependent on 
DNMT1, we sequenced a section (+22 - +293) of bisulfite converted DNA extracted 
from DU145s and hPrECs infected with DNMT1 shRNA.  The methylation pattern 
remained unchanged in the absence of DNMT1 when compared to the cells infected with 
the non-targeting shRNA construct (NT) in DU145s, while subtle increases were 
observed in a single hPrEC DNMT1 knockdown cell line (Figure 2.5C).   According to 
this data, methylation at the AR minimal promoter does not appear to rely on DNMT1.  
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 Figure 2.5 Methylation independent association of DNMT1 with the AR gene.  (A) 
Map of a region of the AR promoter depicting two types of E2F consensus sequences 
+80 → +96 and +13,318 → +13,334 (shown as solid ovals) and +999 → +1,015 (shown 
as open ovals).  Primer flanked regions are designated as sites A, B, and C.  The 243 bp 
region (+22 → +293) analyzed by bisulfite sequencing is indicated.  (B) qPCR analysis 
of target (DNMT1) and non-specific (IgG) ChIPed DNA from BPH-1 cells using primers 
that flank sites A, B, and C.  Primers flanking a region in the PS2 (targeted DNMT1) 
promoter and ABCB1 (non-targeted DNMT1) region were used as ChIP controls.  Data is 
representative of the mean from 3 qPCR reactions and shown as a percent of input with 
the standard error indicated.  (C) Bisulfite sequencing analysis of the 243 bp region in the 
AR minimal promoter in hPrEC compared to DU145 cells infected with both non-
targeting (NT) (control) and DNMT1 shRNA constructs (4-1 and 4-2).  Solid circles 
(methylated) and open circles (un-methylated) were used to represent the methylation 
status of cytosines within CpG dinucleotides. Each horizontal strand of circles depicts a 
separate DNA clone. Lysates were probed on a western blot for AR and actin.  Cell lines 
were also treated with either 1µM 5Aza (5A) or DMSO matched vehicle (V) and 
extracted cDNA was PCR amplified with both human AR and GAPDH.  All data shown 
except for the 5Aza treatments are representative of 3 separate experimental replicates. 
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We additionally demonstrated that AR expression resulting from the downregulation of 
DNMT1 occurred regardless of methylation at the bisulfite sequenced region (+22 - 
+293) in hPrECs. To further asses the possibility for a methylation independent process 
we treated both DU145 and hPrEC lines with a global DNA methylation inhibitor, 5-aza-
2’-deoxycytidine (5-Aza) and observed no change in AR transcription (Figure 2.5C).  
These data point to a possible mechanism of AR repression in normal prostate epithelial 
cell lines that utilizes methylation - independent DNMT1 activity. 
 
DISCUSSION 
In this study we have shown that E2F1 drives the expression of DNMT1 and may 
cooperate with DNMT1 to repress AR transcription in normal undifferentiated prostate 
epithelium. Specifically, exogenous E2F1 down-regulated AR promoter activity 
(decreases in luciferase activity) and mRNA and protein expression, while a dominant 
negative E2F1 construct (DN-E2F1) relieved AR promoter repression by inhibiting 
access of endogenous E2F1 to E2F targeted promoters. All of these observations 
correlated with variations in activation of the E2F-target gene promoter DHFR-Luc, and 
changes in expression levels of endogenous cell cycle regulatory proteins consistent with 
E2F1 activity. The use of functionally debilitating E2F1 mutants suggests that the 
transcriptional regulatory domain of E2F1 comprises this repressive activity possibly 
through the interaction of an intermediary co-repressor.  Based on studies showing that 
DNMT1 is both a target of E2F1 and that it may co-repress some targets with E2F1 (28, 
53), we decided to evaluate the role of DNMT1 in AR repression.  Targeted knockdown 
of DNMT1 relieved AR promoter activity, mRNA and protein expression.  Additionally, 
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DNMT1 directed ChIP showed association of DNMT1 with the AR promoter.  The lack 
of de novo methylation at the minimal AR promoter following loss of DNMT1 suggests 
DNMT1 represses AR expression in a methylation independent manner.  
Sharma et al. have recently demonstrated that E2F1 transactivates the AR gene on 
a depleted RB1 background in an engineered model of castrate resistant prostate cancer 
(62). This observation is interesting in light of our findings in non-transformed prostate 
epithelium in which E2F1 represses AR transcription in the presence of functional pocket 
proteins. Our findings that the Large T antigen facilitates E2F1-mediated repression of 
AR, suggests that E2F1 has roles in both the activation and repression of AR 
transcription. While Sharma et al. provide evidence for a mechanism of AR activation 
that involves the association of E2F1 with specific regions of the AR promoter, our 
results did not find association of E2F1 with these reported sites, but revealed regions 
containing weak E2F1 consensus binding sites downstream of the AR transcription start 
site that demonstrated DNMT1 association instead.  Sharma et al demonstrated a lack of 
E2F1 binding at the only site analyzed by both our labs. While E2F1 failed to promote at 
AR activation at this location, we demonstrated moderate DNMT1 binding associated 
with AR inhibition.  These seemingly contradictory findings might begin to explain how 
E2F1 functions in a more traditional role to activate AR in the absence of RB in prostate 
cancer cells, yet represses AR transcription in normal (non-transformed and non-
immortalized) prostate epithelium in the context of functional RB.   
Although E2F1 is thought to primarily function as a positive regulator of 
transcription, a negative regulatory role of E2F1 has also been described for a number of 
genes (29).  Unlike its positive regulatory function, which is mediated by the direct 
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interaction of E2F1 with DNA, the mechanism(s) for E2F1-mediated negative regulation 
are still largely unknown.   Crowe et. al. identified two putative E2F binding sites in the 
hTERT promoter that were important for E2F1- mediated repression (31).  The E2F1 
mutant (E132) which lacks the DNA binding domain of E2F1 was inefficient at 
repressing hTERT promoter activity, suggesting that the DNA binding domain was 
essential for repression.  In another study, direct repression of the Mcl-1 promoter by 
E2F1 also required the DNA binding domain, but not the transactivation domain (30).  
Koziczak et. al. demonstrated that both the DNA and transactivation binding domains of 
E2F1 were necessary for the negative regulation of uPA and the PA inhibitor (PAI-1) 
genes (29) however, E2F1 repressed promoter activity independently of the pocket 
protein Rb.  We have shown here that E2F1-mediated repression independent of Rb 
pocket protein family members, suggesting that multiple mechanism(s) exist for E2F1-
mediated repression.  We noted that the AR promoter does not contain a strong E2F1 
consensus binding site (TTTGCGG/CG/CAAA), furthermore the E2F1 DNA binding 
domain was not required for repression of the AR promoter suggesting that E2F1 does 
not bind directly to the AR promoter, but cooperates with other regulatory proteins to 
repress AR.  Our data demonstrate that the carboxy-terminal transactivation domain was 
essential for E2F1 suppression of the AR promoter (Figure 2.3) and therefore supports 
two possible models of AR repression.  Several proteins are known to bind to this region 
and regulate transcription including CREB-binding protein (63), MDM2 (64) and 
TRRAP/Tip60 complex (65).  E2F1 may regulate AR promoter activity by forming a 
known repressive complex that includes Rb, HDAC1, and DNMT1 through an as of yet 
undefined domain.  The transactivation domain also interacts with the basal transcription 
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factor IIH (TFIIH) (66) which may facilitate the E2F1 contacts necessary to induce 
transcription at the DNMT1 promoter, increasing DNMT1/AR gene interactions that lead 
to repression (Figure 2.6).  Our findings, along with previous work in the lab, support a 
linear model of AR repression that is reliant on the positive transcription of DNMT1 by 
E2F1. However, the possibility remains for E2F1 to regulate AR expression through a 
complex involving DNMT1 (Figure 2.6). 
We have shown through targeted knockdown of DNMT1 and ChIP analysis that 
the association of DNMT1 with weak E2F consensus sites in the AR gene inhibits 
transcription. A previous study has shown that estrogen receptor (ER) re-expression at 
both the transcriptional and protein level, results from the targeted inhibition of DNMT1 
in ER negative breast cells (67).  DNMT1 is traditionally thought to cause genetic 
repression through methylation, however, the current understanding of methylation 
facilitated repression continues to evolve in the field of epigenetics.  Glypican 3 (GCP3), 
a developmentaly associated gene, is regulated by a promoter methylation independent 
mechanism in human fetal systems (68). Methylation sensitive restriction digests show 
that methylation at the GPC3 promoter is sex specific and occurs regardless of GPC3 
expression status in females, but remains absent in males.  Yakabe et. al. demonstrated 
through ChIP analysis that methyl CpG binding protein 2 (MeCP2), which is usually 
dependent on DNA methylation for genetic interaction, was able to both associate with 
unmethylated promoter sequences and regulate the expression of a subset of selected 
genes (69). Furthermore DNMT1 was reported to repress p21 and BIK in a methylation 
independent manner (70).  Epigenetic regulation possibly involves the 
intercommunication of multiple epigenetic marks to orchestrate the regulation of genetic 
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 Figure 2.6. Schematic representation of AR repression through the E2F1/DNMT1 
axis. The use of either a dominant negative E2F1 construct or a shRNA to knock down 
DNMT1 both result in the downregulation of DNMT1 and subsequent rescue of AR 
expression. E2F1 overexpression experiments suggest that elevated E2F1 levels increase 
DNMT1 protein expression that associates directly with the AR promoter or possibly in 
complex with E2F1 to repress AR. 
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expression.  The simultaneous employment of ChIP and methyl specific primer (MSP) 
analysis, verified the presence of transcription promoting histone modifications (acetyl-
H3K9 and dimethyl-H3K4), associated with unmethylated regions responsible for 
facilitating hTERT expression from a heavily methylated promoter in cancer cells (71).  
The role of methylation independent DNMT1 regulation at the AR promoter may involve 
other epigenetic modifications.  
DNMT1 appears to function in concert with other factors to regulate gene 
expression.  Heterochromatin protein 1 (HP1) GST fusions pull down DNMT1, 3a, and 
3b (72).  Smallwood et. al. and colleagues further demonstrated that methylation by 
DNMT1 in complex with the HP1 proteins was dependent on G9a H3K9me2 using in 
vitro chromatin array methylation assays. DNMT1 is also known to directly interact with 
the enhancer of zeste 2 (EZH2) protein, which mediates H3K27me2/3, in the context of 
the Polycomb repressive complexes (PRC2/3) (73).  Furthermore, DNMT1 was shown to 
associate with histone deacetylase activity during direct interaction with HDAC1 (74) 
and in complex with HDAC2 and corepressor DMAP1 (75).   DNMT1 is likely to 
facilitate repression at the AR promoter through the interaction with many multi-subunit 
complexes. 
 Clearly, mechanisms for AR amplification and mutation play a role in prostate 
cancer progression, however, loss of AR has been reported in a subset of hormone-
independent cancers, including a complete loss in some cases (76, 77).  Highly 
proliferative cells that present with an AR negative phenotype are actually necessary for 
normal prostate development.  Prostate stem cells differentiate into an AR negative 
transit-amplifying (TA) population that is known to transiently undergo multiple rounds 
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of cellular division before terminally differentiating into AR positive luminal epithelium 
(55).  Certain prostate cancers may present with mutations that allow for unhindered TA 
cell proliferation as mentioned in a review by Paul C. Marker (78).  Our findings 
demonstrate that exogenous E2F1 inhibited activation of the AR responsive promoter 
construct (3XHRE-Luc) in a minimally invasive cell line, and that the repression is 
possibly mediated by methylation independent DNMT1 activity at the AR promoter in 
TA cells. The long term effects of E2F1 overexpression in prostate epithelium is still not 
fully understood, however, we propose that the inhibition of AR expression by the 
E2F1/DNMT1 axis may be required for normal growth and development of the prostate 
gland. 
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CHAPTER III 
 
THE E2F1/DNMT1 AXIS DRIVES AR NEGATIVE CASTRATION RESISTANT 
PROSTATE CANCER 
 
ABSTRACT 
The molecular events underlying the clinical recurrence of castration resistant prostate 
cancer (CRPC) remain vague.  CRPC develops through mechanisms that bypass the 
cellular requirement for androgen, by either circumventing normal androgen receptor 
(AR) function or by reducing AR gene expression.  Although AR function has been 
extensively studied in CRPC, less is known concerning the deregulation of AR gene 
transcription in this disease.  We have previously demonstrated that the repression of AR 
gene transcription is mediated by E2F1-dependent induction of the DNA 
methyltransferase 1 gene (DNMT1).  In the current study, we present the first 
comprehensive evaluation of DNMT1 protein expression during the progression of 
human prostate cancer. Immunohistochemical analysis revealed increased nuclear 
DNMT1 staining in localized prostate cancer (p<0.0001) and metastatic prostate cancer 
(p<0.0001) compared to normal tissue. Examination of specific diagnoses revealed that 
Gleason 7 tumors exhibited greater nuclear DNMT1 staining than Gleason 6 tumors  
(p<0.05) and that metastatic tissue exhibited higher DNMT1 levels than Gleason 7 
tumors (p<0.01).  Because CRPC is not uniquely represented in this tissue microarray
66
  
(TMA), we employed a murine model of prostate cancer to specifically evaluate levels of 
E2F1, DNMT1 and AR in experimentally induced CRPC. Only 20% and 30% of benign 
tissues stained for E2F1 and DNMT1 respectively, while 70% of these samples were 
positive for AR.  Conversely, most cancers stained positive for E2F1 (81%) and DNMT1 
(100%) compared to 18% of AR positive cores.   Treating CRPC mice with the DNA 
methytransferase inhibitor 5’-Aza-2’-deoxycytidine (5Aza) reduced DNMT1 staining by 
30%, while AR positive cores increased by 27%. These results demonstrated that an 
inverse correlation exists between DNMT1 and AR during progression of human prostate 
cancer that was also observed in experimentally-induced murine CRPC. Taken together 
these results indicate a functional role for DNMT1-depedent repression of AR expression 
during the emergence of CRPC.   
 
INTRODUCTION 
Castration resistant prostate cancer (CRPC) continues to be associated with significant 
morbidity and is the major cause of prostate cancer related deaths.  Research on this 
disease has focused primarily on the function of androgen receptor (AR) during 
progression to CRPC, but few have considered the loss of AR gene expression itself (1, 2) 
and the possible contribution of AR negative cells to CRPC.  A significant decrease in 
AR expression coincident with the onset of CRPC has been demonstrated in human 
prostate tumors recurring after combined androgen blockade (3). Immunohistochemical 
(IHC) analysis revealed a significant decrease in AR expression in malignant prostate 
tissue procured from patients who failed combination hormone therapy compared to 
untreated individuals (4). More recently, we reported an evaluation of metastatic lesions 
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from CRPC patients that revealed a significant reduction in AR staining when compared 
to hormone naïve cases (5).  However, others have reported a general increase in AR 
expression in castration resistant tissues compared to hormone naïve samples, but 
continue to find CRPC tissue samples with a complete loss of AR expression (3, 6).  Thus, 
the heterogeneous or complete reduction of AR expression appears to be a relevant 
incident during the development of CPRC.  We have recently discovered a novel 
mechanism by which AR transcription is repressed through E2F1-mediated induction of 
the DNA methyltransferase 1 (DNMT1) gene. Based on these functional studies, we 
postulated that this mechanism may play a role in AR repression in a subset of CRPC 
patients.  
 E2F1 is a member of the E2F transcription factor family that plays a traditional 
role in driving S-phase transit of the cell cycle (7) and that functions mainly in 
proliferative cell states.  A genome wide microarray study evaluating gene regulatory 
signatures associated with cancer verified that more than half of the programs analyzed 
were E2F target genes (8), supporting the possibility for E2F1 mediated oncogenic 
transitions.  Both invasive ductal breast (9) and non-small cell lung (10) carcinomas were 
shown to have high levels of E2F1 expression associated with poor prognosis.  Several 
studies have provided evidence supporting a relationship between E2F1 and prostate 
cancer progression. Our group reported findings from tissue microarray (TMA) 
evaluations of metastatic CRPC that revealed significant increases in E2F1 staining when 
compared to hormone naïve cases and that was inversely correlated with reductions in 
AR staining in the same patients  (5).   Zheng et. al. demonstrated that both DU145 and 
PC-3 prostate cancer cell lines rely on E2F1 expression to confer anti-apoptotic 
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characteristics in the presence of various chemotherapies (11).  An expression microarray 
analysis measured high levels of E2F1 cDNA in a set of advanced prostate cancer tumors 
and lymph node metastases (12). The same study also noted that a majority of the cellular 
nuclei within tumors associated with biochemical recurrence exhibited strong E2F1 
staining.  The mechanism by which heightened E2F1 promotes the malignant progression 
of human prostate cancer is still unknown.  It has been suggested that the hyper-
proliferative state of malignant prostate cells is a consequence of unregulated S-phase 
induced by elevated E2F1. We postulate that abnormal E2F1 levels also induce the 
transcription of DNMT1 that leads to AR gene repression and facilitation of tumor 
progression.    
DNA methyltransferase 1 (DNMT1) is a member of the DNA methyltransferase 
family that is responsible for maintaining methylation patterns located in CG 
dinucleotide-rich regions within the genomic DNA.  Methylation of DNA contributes to 
genetic silencing by cooperating with other epigenetic mechanisms to either block 
transcriptional complexes or induce conformational changes in the DNA structure that 
inhibit transcription (as reviewed in (13)).  Aberrant DNMT1 expression and function are 
associated with the progression of various human tumors.  High DNMT1 expression 
levels were observed during the progression of colon (14), bladder (15), gastric (16), and 
pancreatic cancers (17). Little is known about the relationship between DNMT1 and 
prostate cancer progression; however, recent studies demonstrated increased expression 
in advanced disease.  Chen et. al. observed increased DNMT1 levels as prostate cancer 
cell lines transitioned to CRPC (18).  A genome wide cDNA microarray study conducted 
by Tomlins et. al. revealed substantial DNMT1 increases in CRPC compared to primary 
69
  
prostate cancer (19).  Another study reported that prostate tumors exhibited elevated 
DNMT1 immunoreactivity and protein content compared to benign prostate tissue (20).  
The TRAMP mouse model of prostate cancer demonstrated increased DNMT1 
expression during progression to poorly differentiated and metastatic (21, 22). In addition, 
we have shown that 5-Aza treatment completely prevents the histopathological 
progression and its associated lethality in TRAMP mice (22). Other efforts to uncover 
common abnormalities amongst heterogeneous prostate cancer cases have identified a 
variety of consistently hyper-methylated genes that may represent the catalytic signature 
of DNMT1 in prostate cancer progression (23, 24). Collectively, these observations 
support a functional role for DNMT1 during prostate cancer progression that may include 
the repression of the AR gene in the development of CRPC.  
This study will demonstrate a correlative relationship between E2F1, DNMT1, 
and AR during human prostate cancer progression to treatment-resistant and recurrent 
disease. We will also demonstrate the presence of this axis in experimentally induced 
CRPC using the TRAMP prostate cancer model that when considering our findings 
human samples supports a functional role for this axis during the emergence of AR-
negative CRPC. 
 
MATERIALS AND METHODS 
 
Analysis of human prostate cancer progression tissue microarray.  Tissue microarrays 
(TMA) containing cores procured from both human and mouse tissues during prostate 
cancer progression were immune-stained to detect the expression of E2F1 DNMT1 and 
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AR.  The human TMA consists of 90 patients represented by 270 cores containing 
normal, bening prostatic hyperplasia (BPH), BPH stromal nodules, prostate intraepithelial 
neoplasia (PIN), prostatic atrophy, proliferative inflammatory atrophy (PIA), and both 
localized and metastatic prostate cancer tissues.  Benign tissues were acquired by 
cystectomy, prostatectomy, and transurethral re-sectioning from 30 patients.  Pre-
cancerous (PIN and Hyperplasia) and localized disease samples were obtained from 
radical prostatectomy specimens from patients who had their prostate removed for 
prostate cancer.  Metastatic sections from distant tissue sites were acquired through rapid 
autopsy from 10 patients who were non-responsive to cancer therapies.   
 
Analysis of TRAMP tissue microarray.  The 333 cores present in the mouse TMA were 
procured from a total of 111 wildtype and TRAMP mice that were either castrated, sham 
operated, or treated with 5’ –Aza-2’-deoxycytidine (5Aza) during a cancer survival study 
(25). Treatments and operations were done either independently or in combination, while 
mice receiving mock operations or PBS treatments served as controls.  Mice lived the 
longest after castration followed with 5Aza treatments and showed significantly higher 
survival rates compared to mice receiving castration alone.  All mice tissues evaluated in 
the present study, however, were taken from mice sacrificed at 24 weeks of age. 
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RESULTS 
 
Immunohistochemistry and quantitative analysis of DNMT1 in human tissues.  We 
have previously reported the inverse correlation between E2F1 and AR during prostate 
cancer progression to castration resistant disease (5).  Further studies by our group 
demonstrated that existence of an AR regulatory mechanism controlled by E2F1-
dependent activation of the DNMT1 gene that acted as a functional intermediary during 
AR repression.  To evaluate any patho-mechanical roles of DNMT1 in human prostate 
cancer and the emergence of CRPC, we evaluated a human TMA comprised of various 
stages or localized prostate cancer as well samples of metastatic disease.  The mean 
nuclear intensity (MNI) scores for DNMT1 staining were determined in of 27 cores from 
normal adjacent prostate tissue, 59 Gleason scored cores, and 19 metastatic cores from 
distal tissue sites. DNMT1 nuclear staining significantly increased from normal to 
metastatic prostate cancer (Figure 3.1A).  Metastatic cores with a Mean Nuclear Intensity 
(MNI) score of 1.95 had a significantly (p<0.0001) higher nuclear staining intensity than 
localized tissue cores with an MNI of 1.05.  Normal tissue cores showed the least nuclear 
staining (MNI=0.19) and was significantly (p<0.0001) lower than levels observed in 
localized prostate cancer tissues (Figure 3.1B).   
 A detailed look at the progression from normal to metastatic prostate cancer 
revealed significant nuclear intensity changes amongst specific diagnoses.  Tissues with a 
Gleason score of 7 (G7) showed significantly ( p<0.05) greater nuclear DNMT1 staining 
(NMI=1.26) than G6 graded cores (MNI=0.5) (Figure 3.2A and 3.2B).  Metastatic cancer 
samples (MI=1.95) with the highest nuclear DNMT1 levels were significantly (p<0.01) 
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 Figure 3.1 Nuclear DNMT1 expression during prostate cancer progression.  A) 
Histological representation of human tissue cores recovered from the rapid autopsy 
program.  Normal, localized, and metastatic prostate cancer representations magnified 
respectively both at 20X (a-c) and 40X (d-f).  B)  Mean nuclear intensity scores are 
presented in a bar graph for each diagnosis normal tissue (n=27 cores), localized cancer 
(n=59 cores), and metastatic cancer (n=19 cores).  Tukey’s multiple comparison test 
demonstrates statistical significance (p-value < 0.001). 
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 Figure 3.2 Nuclear DNMT1 expression according to Gleason score.  A) Nucler 
DNMT1 staining across normal (n=27 cores), Gleason 6 (G6) (n=8 cores) and G7 (n=27 
cores) localized prostate cancer, and metastatic categories (n=19 cores).  B) The mean 
nuclear intensity score are shown via bar graph.  Tukey’s multiple comparison test 
demonstrates statistical significance (p-value<0.05,  p-value < 0.01,  and p-value < 
0.0001). 
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higher than G7 staged localized prostate cancer (Figure 3.2B).  These data demonstrated 
that localized prostate cancer samples show variations in DNMT1 immunostaining that 
are dependent on tissue grade.  Nuclear DNMT1 staining was strongest in metastatic 
tissues procured from patients that were non-responsive to cancer therapies. The evidence 
supported a possible role for DNMT1 during CRPC as an intermediary involved in AR 
repression and prompted further analysis. 
 
Analysis of AR Regulation through the E2F1/DNMT1 Axis in the TRAMP Mouse.  
We used the Large T antigen (Tag) mouse model of prostate cancer (TRAMP) for 
analysis of E2F1, DNMT1 and AR in tumorigenesis. SV-40 Tag is driven by the rodent 
probasin promoter that preferentially binds to hypophosphorylated Rb, thereby releasing 
E2F family members and disrupting G1 cell cycle checkpoints.  We hypothesized that 
increased E2F1 activity in the TRAMP mouse, results in the modulation of downstream 
E2F1 target genes such as PCNA and the E2F-mediated repression of AR.  To test this 
hypothesis, we examined prostate tissue from C57Bl/6 and TRAMP mice at 24 weeks of 
age with poorly differentiated prostate cancer.  Detailed assessment of proliferation, E2F 
activation, and expression of either: E2F1, DNMT1, or AR was performed on paraffin-
embedded tissue sections.  Tag was present in prostate tissue of all transgenic animals 
with poorly differentiated prostate cancer, but absent in tissues from C57Bl/6 mice 
(Figure 3.3A (a,f)).  Levels of E2F1 were also comparably higher during poorly 
differentiated cancer (Figure 3.3A (c,h)).  E2F1 activity and cell proliferation were 
assessed by staining for proliferating cell nuclear antigen (PCNA).  Epithelial cells in 
normal prostate tissues were predominantly negative for PCNA staining (Figure 3.3A (b)), 
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 Figure 3.3 E2F1, DNMT1, and AR expression during tumorigenesis in the TRAMP 
model.  A) Immunohistochemical staining of normal prostate tissue from C57Blk/6 
control mice (panels a-e) and prostate cancer from a 24 week old TRAMP mouse (panels 
f-j) at 100X magnification.  Sections were stained for Large Tag (panels a, f), PCNA 
(panels b, g), E2F1(c,h), DNMT1(d,i), and AR (panels e,j)  B)The number of tissue cores 
staining positive for either E2F1 (n=49 normal and n=73 cancer), DNMT1 (n=62 normal 
and n=80 cancer), or AR (n=67 normal and n=67 cancer) are shown as a percent of the 
total available within each diagnosis (normal or cancer) group. 
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indicating both low E2F1 activity and a low proliferative index. However increases in 
PCNA staining (Figure 3.3A (g)) in addition to Cyclins A and E protein (data not shown) 
were observed in TRAMP mice with poorly differentiated tumors compared to C57Blk/6 
mice at 24 weeks.  This increase in both cell proliferation and E2F1 activity was 
associated with a concomitant increase in nuclear DNMT1 (Figure 3.3A (d,i)) expression 
with subsequent decreases in AR protein (Figure 3.3A (e,j)).  Conversely, normal tissues 
showed strong AR nuclear staining.  Together, these results demonstrate that increased 
E2F1 expression correlates with increased cell proliferation and expression of E2F-target 
genes (PCNA and DNMT1) with a concomitant down-regulation of AR in prostate 
epithelial cells during prostate cancer progression in the TRAMP model. 
We constructed a TMA from tissues procured from a previous treatment study of 
TRAMP mice (25) (Figure 3.4). This TMA was used to evaluate normal and tumor 
diagnosed tissue by immunostaining of E2F1, DNMT1 and AR.  Only 20 and 30% of all 
benign tissue cores stained positive for E2F1 and DNMT1 respectively, while 70% of the 
cores stained positive for AR.  Conversely, a large proportion of the tissues diagnosed 
with cancer stained positive for E2F1 (80.8%) and DNMT1 (100%) compared to 17.9% 
of the cores that stained positive for AR (Figure 3.3B).  The high levels of E2F1 and 
DNMT1 present during low AR expression continue to support a mechanism for the 
regulation of AR by the E2F1/DNMT1 axis in vivo. 
 
Analysis of E2F1, DNMT1, and AR in CRPC of TRAMP mice.  To assess AR 
repression in association with elevated expression of E2F1 and DNMT1 during CRPC in 
vivo, we measured expressional changes in tissue cores procured from a murine model of 
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 Figure 3.4 TMA treatment schedule.  Tissue procured from treated wild type and 
TRAMP mice were used to construct the mouse TMA. Treatment with either vehicle 
(PBS), 5-aza, or castration were initiated at 15 weeks of age.  Drug injections were 
administered 3 times a week for 10 weeks.  An adaptation of a figure created by Zorn et. 
al. Clin Cancer Res, 2007. 
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CRPC (25) (Figure 3.4). CRPC was recapitulated in the TRAMP model by castrating 
mice with fully developed tumors at 15 weeks of age (25, 26).  TRAMP mice undergoing 
castration were additionally treated with 5Aza, a DNA methylation inhibitor shown to 
enhance overall survival and decrease cancer pathology (25).  We observed a 30% 
decrease in tissues stained with DNMT1 from castrated mice treated with 5Aza compared 
to those receiving PBS (Figure 3.5B).  The percent of AR positive cores, however, 
increased by 27% after 5Aza treatments (Figure 3.5B).  The number of tissues 
immunostained with E2F1 showed no significant change in cores taken from castrated 
mice treated with 5Aza (Figure 3.5B).  Representative tissue from castrated mice that 
maintained normal glandular morphology following 5Aza treatment show intense nuclear 
AR staining compared to decreases in DNMT1 (Figure 3.5A). These data demonstrate 
that AR positivity increases in both the absence of methylation and in the presence of 
diminished DNMT1 levels in vivo. 
 
DISCUSSION 
AR repression through the E2F1/DNMT1 axis may be a mechanism by which cells 
maintain an undifferentiated yet aberrantly proliferative state during progression to CRPC.  
We demonstrated that nuclear DNMT1 like E2F1 increases during human prostate cancer 
progression to metastases.  These expressional changes along with decreases in AR 
expression are recapitulated in TRAMP mice with poorly differentiated prostate cancer. 
We obtained a better understanding of the molecular changes occurring during CRPC 
after treating castrated TRAMP mice with 5Aza. The increase in epithelial AR levels 
following the inhibition of DNA methylation, suggests that AR repression may involve 
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 Figure 3.5 E2F1, DNMT1, and AR expression consequent to castration in the 
TRAMP model.  A)  The shown immunostained cores are representative of tissues taken 
from castrated TRAMP mice treated with either PBS (a-c) or 5-Aza (d-f).   The 
histological expression of E2F1 (a,d), DNMT1 (b,e), and AR (c,f) were viewed at a 20X 
magnification.  B) The castrated TRAMP cores staining positive for either E2F1 (n=24 
PBS treated and n=28 5-aza treated), DNMT1(n=28 PBS treated and n=28 5-aza treated), 
and AR (n=21 PBS treated and n=29 5-aza treated) are shown as a percent of the total 
amount of cores available in either PBS or 5-Aza treated cohorts. 
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DNMT1 catalytic activity during CRPC.  The correlation between late stage/metastatic 
prostate cancer and AR repression through the E2F1/DNMT1 axis presents possible 
prognostic and therapeutic targets. 
This study is the first comprehensive histopathological evaluation of DNMT1 in 
human prostate cancer.  The significant correlation between cancer progression and 
increased DNMT1 expression supports a possible use for DNMT1 as a diagnostic marker 
for certain prostate cancers.  A previous study reports that gastric cancer patients with 
high epithelial DNMT1 expression have a significantly higher risk of death (27). 
Elevated DNMT1 expression was additionally shown to indicate the presence of 
metastatic prostate cancer in the TRAMP model. Kinney et al. observed a loss in prostate 
cancer metastases after DNMT1 levels were knocked down in TRAMP mice (21).  Our 
study reveals DNMT1 expressional changes correlate with stage (localized vs. metastatic) 
and histological grade, with increased intensity for both more advanced disease and 
higher grade tumor. The significant difference in mean nuclear intensity (MNI) between 
Gleason grade 6 and 7 is of interest for potential clinical application in the setting of 
active surveillance. There is an ever expanding repertoire of markers being applied to 
small low grade (Gleason 6 and 7) tumors in an effort to triage patients into active 
surveillance and definitive treatment categories based on scientific data. Therefore 
DNMT1 staining of prostate biopsy samples alone or in combination with other markers 
may be of clinical value in this setting and deserves further study. 
AR repression is one molecular event observed during CRPC.  We show an 
increase in the amount of AR positive tissues acquired from castrated TRAMP mice 
(CRPC model) after treatments with 5Aza and suggest that AR repression is facilitated by 
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DNA methylation.  AR has been shown to be methylated in a series of metastatic human 
prostate cancer cell lines. In addition to being methylated within specific regions, AR 
gene expression is rescued in M12 cells (AR negative metastatic lines) (28), androgen 
independent TSU-PR1 cells (29), and rat cells (androgen independent tumor cell line) (30) 
after 5Aza treatments.  Kinoshita et. al. also identified hypermethylated regions within 
and downstream of the AR promoter that were common amongst AR negative castration 
resistant cell lines (31).  A study of localized prostate cancer samples revealed that AR 
gene methylation was specifically occurring during late stage prostate cancer (32).  A 
comparison of prostate cancer tissues showing AR methylaion demonstrated that 100% 
of the CpG sites analyzed were methylated in samples from CRPC patients compared to 
50% of the sites being methylated in samples acquired from localized prostate cancer 
tumors (33).  These data further support a mechanism for AR regulation via methylation 
in our model of CRPC. 
 DNMT1 facilitates genomic silencing by predominately maintaining the state of 
DNA methylaion but is also known to utilize de novo pathways.  We have previously 
observed the repression of AR by E2F1 through DNMT1 as an intermediary (Valdez et al 
unpublished observations).  Our current study demonstrated that DNMT1 increases 
during the progression of human prostate cancer to metastatic and CPRC disease.  Higher 
DNMT1 levels may facilitate methylation dependent silencing and suppression of AR 
activity.  Evidently, DNMT1 levels are important in maintaining abnormal levels of 
methylation.  Robert et al. showed that the downregulation of DNMT1 with anti-sense 
oligonucleotides in the HCT116 colorectal cells significantly increased the amount of 
unmethylated DNA (34). High DNMT1 levels and increased genomic methylation have 
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also been reported during the metastatic progression of prostate cancer in the murine 
TRAMP model (21).  Contrary to these findings, Hoffmann et al. reported that DNMT1 
is not responsible for methylation during prostate cancer (35), however, this study did not 
globally assess genome-wide methylation. DNMT1 may therefore repress AR expression 
through methylation during late stage prostate cancer and CRPC. 
The substantial increase in AR and decrease in DNMT1 following 5Aza treatment in our 
TRAMP CRPC model suggests that AR is regulated by DNMT1 dependent methylation, 
which is a conceivable therapeutic target.  Methylation inhibitors such as 5-Aza, were 
shown to be effective in the treatment of myelodisplastic disease (36).  The short half-life 
and high toxicity of 5Aza, however, create many complications for patient treatment.  
More suitable treatments may utilize less toxic methylation inhibitors such as Zebularine, 
but the drug is only effective at unreasonably high doses (37).  Alternatives might 
directly target DNMT1 through the use of siRNA oligonucleotides.  Knockdown of 
DNMT1 levels was shown to reduce proliferation and increase apoptosis in both gastric 
and esophageal squamous cell carcinoma cell lines (38, 39).  The delivery of siRNA 
oligonucleotides to tumorigenic cells remains problematic.  Future studies will need to be 
conducted to further evaluate the therapeutic potential of DNMT1 as well as the 
predictive value of DNMT1 in CRPC disease.  
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CHAPTER IV 
 
DISCUSSION 
 
Our studies sought to understand the proliferative nature of castration resistant prostate 
cancer (CRPC) by evaluating normal cellular division during prostate development.  
Considering that AR defines a differentiated and proliferative endpoint in prostate 
epithelium, we were curious how AR expression was repressed in the proliferative 
undifferentiated transit amplifying (T/A) population.  An AR repressive mechanism may 
contribute to the proliferative progenitor-like phenotype of T/A cells.  Results from our 
studies suggest that E2F1 represses AR through a DNMT1 mediated process.  We 
assessed the potential for the E2F1/DNMT1 axis to repress AR during the development 
of castration resistant prostate cancer (CRPC), a cancer transition known to show 
decreases in AR expression.  A substantially greater amount of castrated TRAMP CRPC 
tissue stained positive for E2F1 and DNMT1 compared to AR, consistent with a 
mechanism of AR repression by the E2F1/DNMT1 axis.  We also demonstrate that 
contrary to the repression of AR in a model of CRPC, AR regulation by the 
E2F1/DNMT1 axis in non-malignant cells appears to be methylation independent.  These 
findings imply that altercations in the E2F1/DNMT1/AR regulatory axis may lead to a 
methylation dependent mechanism during CRPC.   
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 E2F1 mediated AR repression 
Historically, E2F1 is thought to function as a transcriptional activator (1),  however, 
recent research suggests E2F1 may function as a repressor of gene transcription.  The 
E2F1 transactivation domain was required for the repression of both the PA inhibitor 
gene and the Mcl-1 gene (2, 3).   All reported transcriptional inhibition by E2F1 was 
shown to be DNA binding domain dependent.  Our studies demonstrated that the 
transactivation domain greatly contributed to the repression of AR by E2F1, while the 
DNA binding domain demonstrated little to no effect on transcriptional silencing.  We 
considered that E2F1 either utilizes the transactivation domain to complex with a group 
of transcriptionally repressive proteins or promotes the expression of downstream genes 
that facilitate repression.  As a result, we identified DNMT1 as a functional intermediary 
for AR repression by E2F1.  We suggest that E2F1 may complex with DNMT1 and/or 
directly upregulate repressive DNMT1 levels.  
E2F1 is shown to form a repressive complex with Rb.  Rowland et. al. 
demonstrated that Rb binding domain mutants of E2F1 disrupt the endogenous repression 
of the p19ARF gene (4).  The implications that E2F1 forms a repressive complex with Rb 
are further supported by evidence showing that reporters are silenced by the recruitment 
of Rb to E2F consensus site in the promoter (5).  Similar repression of E2F binding site 
containing reporter constructs was facilitated by an E2F1/Rb complex that included 
DNMT1 and HDAC1 (6).  These studies suggest that highly conserved E2F binding sites 
are required to recruit Rb repressive complexes to the promoter.  Our studies, however, 
demonstrated that the AR promoter presents weak E2F consensus sites and that an E2F1 
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DNA binding mutant was still capable of partial AR gene repression.  While our findings 
fail to support a mechanism that explains an Rb recruitment complex, the transactivation 
domain is clearly required for AR repression.  Our explanation for this observation is that 
the E2F1 DNA binding mutant is still able to contribute to the formation of an as of yet 
undefined inhibitory complex that incorporates DNMT1, through transactivation domain 
contacts.  In the absence of E2F1 facilitated gene targeting, DNMT1 may mediate multi-
subunit recruitment to the DNA through CXXC domain interactions with CpG 
dinucleotides. Repression by the E2F1 DNA binding mutant reveals one possible mode 
of AR regulation by E2F1.  In addition to facilitating repressive complexes, E2F1 may 
target the transcription of a genetic silencer.   
E2F1 may directly interact with the gene that is transcribed or target the 
expression of an intermediary that regulates the expression of downstream genes.  A 
microarray analysis of newborn mice livers demonstrated that endogenous E2F1, in 
addition to activating transcription, contributed to the repression of a small cohort of 
genes (7).  E2F1 may either indirectly or directly mediate transcriptional repression.  
McCabe et. al. showed that E2F1 directly coordinates the transcription of DNMT1, a 
major epigenetic modifier involved in gene silencing.  We showed that AR expression is 
re-expressed in AR negative cells following DNMT1 downregulation.  We suggest that 
E2F1 upregulates DNMT1 to repress AR expression. 
We provide further evidence to support transcriptionally repressive roles for 
E2F1.   We propose two potential mechanisms by which E2F1 mediates the regulation of 
AR.  1) E2F1 either forms a complex containing DNMT1 and/or 2) transcriptionally 
upregulates DNMT1 to repress AR (Figure 4.1). 
90
 Figure 4.1 Schematic of AR repression by E2F1.  E2F1 targets the transcription of 
DNMT1 which binds to and represses the AR gene.  The E2F1 transactivation domain 
assists in the formation of a DNMT1 containing repressive complex that is still functional 
in the absence of the DNA binding domain.  
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 Methylation Independent Regulation by DNMT1    
DNMT1 is generally believed to function as an enzyme that regulates gene expression 
through the methylation of DNA. However, few have explored the possibilities for 
methylation-independent regulation.  We showed that AR expression was unchanged 
following administration of the DNA methylation inhibitor, 5-aza.  AR expression in AR 
negative cells was achieved through the downregulation of DNMT1, which additionally 
failed to change the methylation status of the minimal promoter.  We postulate that 
DNMT1 regulates AR in a DNA methylation independent manner.  Szyf et. al. 
demonstrated that DNMT1 utilizes a non-DNA-methylating alternative to regulate both 
BIK and p21 expression (8).  The findings implied that suppressive DNMT1 interactions 
with promoter bound Sp1 and 3 factors inhibited the transcriptional activity required for 
gene expression.  Similar to E2F1, DNMT1 regulatory activity in the absence of DNA 
methylation is potentially dependent on interactions with specific multi-unit protein 
subsets. 
 DNMT1 may facilitate DNA methylation independent AR repression through the 
establishment of chromatin modifying complexes (Figure 4.2).  DNMT1 may function 
through known repressive mechanisms dependent on the recruitment of HDAC1 and 2 
deacetylase activity by defined interaction domains (9, 10).  DNMT1 is additionally 
found to directly interact with the polycomb repressive complex 2 (PRC2) protein EZH2, 
which silences gene expression through histone methylation (H3k27me2/3) (11).  We 
observed the DNA methylation independent regulation of AR in cells that recapitulate a 
progenitor-like phenotype.  EZH2 knockouts, resulting in embryonic lethality (12), 
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 Figure 4.2 DNMT1 repressive complex stimulates the formation of 
heterochromation.  The following DNMT1 domains (N-terminal, CXXC, BAH 1 and 2, 
and catalytic) are represented in the schematic.  Unmethylated cytosines depicted by open 
circles and are shown in contact with the CXXC domain.  E2F1 interactions with the 
BAH domains facilitates the recruitment of the PRC2 complex which guides histone tail 
methylation (Me) by EZH2.  HDAC 1 and 2 remove of histone tail acetyl groups (Ac) by 
binding to the N-terminal domain.  
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suggest that the protein plays a critical role in development and functions to maintain 
progenitor-like properties.  AR repression in our cell models may therefore occur through 
EZH2 facilitated histone methylation.  The methylation of H3K27 by EZH2 may 
additionally cooperate with HDAC (1-2) deacetylation to facilitate AR silencing.  The 
sequential treatment of cells with an inhibitor (DZNep) of EZH2 dependent methylation, 
followed by a histone deacetylase inhibitor (TSA), resulted in the re-expression of 
CDKN1C (13).  Chromatin modification is a mechanism of repression that may operate 
independent of methylation. 
 DNMT1 has the potential to regulate gene expression through non-DNA 
methylating mechanisms.  The structural domains facilitate interactions that promote 
chromatin condensation and gene silencing.  We provide an example of gene regulation 
by non-methylating DNMT1 and suggest a mechanism that involves both histone 
methylation and deacetylation.  DNMT1 targeted histone modifications, in the absence of 
DNA methylation, may enable a repressive state that is more suitable for temporally 
coordinated expression.  Further studies might examine the epigenetic states of the AR 
gene during prostate epithelial differentiation.  
   
Transcriptional regulation of the AR gene  
A comprehensive understanding of AR gene repression is still lacking.  The presence of 
cis-elements and multi-protein regulatory domains were observed to negatively regulate 
AR promoter activity (14, 15).  We present evidence suggesting that DNMT1 regulates 
AR gene repression.  The abundance of GC rich sequences in the AR promoter (16) 
provides sites for repressive DNMT1 interactions.  Our studies further verify that the 
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regulation of AR transcription is cell-type specific (17).  We postulate that DNMT1 
facilitates DNA methylation independent repression in cells, recapitulating a non-
malignant phenotype while silencing gene transcription by methylating the AR promoter 
in CRPC. 
Our nonmalignant cell model demonstrated AR repression that was independent 
of DNA methylation.  According to our DNMT1 directed ChIP findings DNMT1 
demonstrated strong association with a section of the first AR intron.  DNMT1 
interactions at the intron may affect the overall regulation of the gene.  Understanding 
that the AR expression is both tissue and differentiated state specific implies that intronic 
sequence elements may exist to coordinate appropriate spatial and temporal expression.  
The second intron of the AGAMOUS (AG) gene was shown to be required for normal 
patterns of expression for the AG:beta-glucoronidase gene fusion reporter in plants (18). 
Kamachi et. al. additionally defined a location in the third intronic region of the lens 
specific delta1-crystallin gene that facilitates regulatory factor interactions to restrict 
broad abnormal expression (19).  The intron is also shown to enhance gene expression as 
demonstrated by the first intron in the rat growth hormone gene (20).  DNMT1 may 
facilitate AR repression through interactions with a possible regulatory element in the 
first intron (Figure 4.3A). 
DNMT1 might inhibit the binding of transcriptional activators to enhancer 
elements within the first intron (Figure 4.3).  NF-kappa-B was shown to negatively 
regulate rat AR transcription by blocking the kappa-immunoglobulin light chain enhancer 
from interacting with a location 570 bps upstream of the transcription start site.  
However, no conservation was observed between the human kappa-light chain enhancer 
95
consensus site (ATTTGCATA) (21) and a region spanning ~2,000 bp of the intronic site 
associated with DNMT1 in our ChIP analysis.  A regulatory sequence may still exist 
considering the prevalence of numerous non-coding genomic sequences with unknown 
functions.   
AR regulation during CRPC is alternatively shown to be associated with 
methylation that maybe mediated by DNMT1.  Repressive AR gene methylation at the 
DNA level is directly shown through bisulfite sequencing or inferred from 5-aza (DNA 
methylation inhibitor) induced gene re-expression in many castration resistant cell lines 
(22-24).  We demonstrated that 60.71% of the CRPC TRAMP mice treated with 5Aza 
showed AR positivity compared to 33.33% of the untreated cohort.  The large increase in 
the amount of AR positive tissues from treated mice implied that AR repression was 
facilitated by DNA methylation during CRPC.  DNMT1 is possibly responsible for 
methylating the promoter, considering the high amount of castration resistant tissue that 
stained positive for DNMT1.  Feltus et. al. demonstrated that a group of CpG islands 
(CGI) were hypermethylated following the overexpression of DNMT1 (25).  A CGI is 
present in the AR promoter region and is consequently susceptible to the 
hypermethylation observed at CGIs in genes during cancer.  Abnormal levels of DNMT1 
may therefore repress AR expression during CRPC by hypermethylating the promoter 
(Figure 4.3B). 
The seemingly conflicting functional roles for DNMT1 during normal 
development and the onset of CRPC are reconciled within the context of protein 
complexes.  DNMT1 was observed to methylate and silence genes while in complex with 
HP1 (26), but was also shown to facilitate methylation independent repression while 
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 Figure 4.3 Two modes of AR repression facilitated by DNMT1.  (A) DNMT1 
competes with an enhancer factor (EF) at a site in the first intron of the AR gene and 
inhibits the expression of AR.  (B)  DNMT1 accumalation results in the hypermethylation 
of a CpG island spanning across transcription start site II. 
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interacting with an HDAC2/DMAP1 co-repressor complex (9). These findings suggest 
that specific protein interactions may regulate DNMT1 dependent methylation.  Kar et. 
al.  reported a number of mutated proteins expressed in various cancers that are able to 
form aberrant interactions (27). Compared to normal prostate development, abnormal 
complex formation during CRPC potentially recruits DNMT1 to hypermethylate and 
silence genes.  As a result, DNMT1 facilitate repression appears to be both dependent and 
independent of methylation.  We demonstrated that these divergent modulatory roles may 
correspond to a cell type specific environment. 
 
Differentiation within the Context of AR Expression 
We have defined an AR repressive mechanism that is associated with undifferentiated 
proliferative epithelium in the prostate and therefore suggest that AR expression may 
facilitate differentiation.  AR expression has been shown in the terminally differentiated 
luminal epithelium of the developing prostate (28).  Activated AR may promote the 
transcription of genes that drive epithelial differentiation.  Alternatively, an established 
differentiated state may support the expression of AR.  The latter alternative would 
suggest that AR is not required for epithelial differentiation.  Although active AR may 
not be sufficient to induce differentiation, evidence exists to support the notion that 
epithelial differentiation requires AR activity.    
The removal of AR from normal prostate epithelium results in a corresponding 
loss of differentiation.  Wu et. al. knocked out (KO) AR in the luminal epithelium of 
mouse prostates and observed de-differentiating morphological changes in the ventral 
prostate (29).  AR KO mice at 9 weeks of age had decreased glandular infolding and 
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showed a pronounced transition of luminal epithelium from tall columnar to small 
cuboidal cells typical of a less differentiated phenotype. The authors show a decrease in 
the expression of differentiation markers (PSP94 and NKX3.1), however, these genes are 
androgen activated and expressional levels coincide with AR activity.  The re-expression 
of AR post de-differentiation might reverse the effects and demonstrate a substantial role 
for AR in differentiation.  
AR expression is evidently required for the differentiation of the luminal 
epithelium in the ventral prostate.  Further studies might determine how functional AR is 
involved in differentiation.  Overexpression of AR in AR negative cell lines such as, 
BPH-1 and PC-3, was shown to reduce proliferation (30, 31), however differentiation 
was not evaluated in these studies.  The directed expression of AR via a k5 promoter in 
the basal epithelium may induce differentiation in vivo.  Although, transgenic 
overexpression of the AR gene may promote genetic abnormalities which further 
contribute to tumorigenesis.  AR activation potentially facilitates differentiation during 
normal prostate development.        
  
DNMT1 as a prognostic marker 
Treatment plans for patients with prostate cancer are diagnosis dependent.  A number of 
parameters are considered (Prostate specific antigen (PSA) levels, gleason score, staging, 
ect.) to prescribe the most efficient therapy.  Active surveillance, an intensive monitoring 
program involving continual checkups and prostate screens, was recently shown to 
extend the quality of life for patients with localized low risk prostate cancer (32) by 
reducing overtreatment.  The surveillance program is offered to patients that match the 
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established diagnostic criteria (PSA < 10ng/ml, stage ≤ T2a, and Gleason score ≤ 6) (32).  
Immediate treatment occurs at a Gleason score of 7 (G7). However, scores may mislead 
options to withhold treatment.  
Although Gleason scores provide definitive information on the status of prostate 
progression from localized to metastatic cancer (as reviewed in (33)) errors may occur in 
the assignment of numerical values.  Pinthus et. al. revealed that 61.8% of the G6 
diagnosed biopsies were underscored compared to the G7 evaluated tissues following 
radical prostatectomy (34).  The decision to either treat or enroll patients with G6 
biopsies into the active surveillance program is confounded by these findings.  Molecular 
panel studies have attempted to better define prostate cancer progression, however, the 
heterogeneous nature of prostate cancer continues to cause prognostic marker 
inconsistencies (35).   We observed a significant increase in the DNMT1 nuclear staining 
of tissues procured from G7 graded tumors compared to G6.  Our samples were obtained 
by radical prostatectomy and therefore provided more reliable Gleason scores.  DNMT1, 
as a result, may be a candidate for a prognostic marker that better differentiates between 
G6 and 7 graded tumors evaluated by biopsies.  An improved diagnosis will help to better 
manage treatment options for low grade prostate cancer.    
Quantitative based analyses of DNMT1 may function as a predictive 
measurement for certain prostate cancer treatments.  Specific levels of DNMT1 may help 
to predict a point at which methylation inhibiting drugs such as 5-aza are most effective 
in the treatment of certain prostate cancer subtypes.  Treatments with 5aza were shown to 
significantly increase the survival of TRAMP mice (36, 37) but had subtle effects on 
human patients suffering from late stage CRPC (38).  A study evaluating the methylation 
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of several tumor related genes noted that the highest frequency in promoter CGI 
hypermethylation occurred in cancer tissue with a Gleason score ≥ 7.  DNMT1 levels 
assessed in biopsies may help to define a temporally finite point to initiate anti-
methylating treatments that prevent the onset of hypermethylation confining the cancer to 
a more treatable state.  Drug administration at the correct time may prevent the transition 
from G6 to G7 prostate cancers or divert androgen independent pathways that lead to 
CRPC. 
Expressional measurements of DNMT1 may be used to determine appropriate 
treatment options.  We have described a mechanism of AR repression facilitated by 
DNMT1 that may be characteristic of androgen independent prostate cancer cells.  
Further evidence suggests that silencing by DNMT1 in CRPC may occur in a methylation 
dependent fashion.  More comprehensive studies on DNMT1 levels during prostate 
cancer may help to illuminate novel therapeutic pathways.   
 
 
Future Directions  
Our studies have established two possible mechanisms of AR regulation in prostate 
epithelium.  We suggest that DNA methylation independent repression by DNMT1 
contributes to the maintenance of the progenitor cell phenotype, while AR repression 
during CRPC via DNMT1 dependent hypermethylation facilitates an undifferentiated 
proliferative phenotype.  Future studies might examine the stromal signaling factors that 
may utilize our mechanism of repression to regulate epithelial AR expression in vivo.  
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Additionally, regulation of AR at the chromatin level may reveal new regulatory 
complexes and epigenetic modifying interactions.   
 Much is unknown about the in vivo cross talk between the mesenchyme and 
epithelium of the prostate gland.  Stromal signals may either induce or inactivate the 
E2F1/DNMT1/AR repression axis described herein.  The use of tissue recombination 
techniques as described by Chuna et. al. (39) in the analysis of AR deficient epithelium, 
may provide a workable experimental model.  The fibroblast growth factor receptor 2 
(FGFR2) shown to mediate paracrine signaling (andromedin) from the stoma via FGF7 
(40), would be targeted as a critical point for stromal and epithelial communication.  
FGFR2 knockout mouse epithelial cells that are AR negative would be mixed with 
normal mouse stromal cells and grafted on the renal capsule of the mouse kidney.  Tissue 
sections of an either developed or undeveloped prostate would be stained with AR to 
determine the effect of a lack of andromedin signaling through the FGFR2 receptor on 
AR expression.  If AR expression is deregulated, further analysis of DNMT1 and E2F1 
expression may reveal mechanisms linking andromedin signaling to AR regulation.  
DNMT1 knockout epithelial cells that are AR negative would also be assessed within the 
context of the tissue recombination model.  The analysis may provide further insight to 
the role that the mesenchyme has during prostate epithelial differentiation. 
 The androgen receptor regulation may involve epigenetic modifying mechanisms 
that occur at the chromatin level.  We currently used DZNep (EZH2 inhibitor) and TSA 
(broad HDAC class I and II inhibitor) to determine the requirement for chromatin 
modifiers during AR repression in PrEC and BPH-1 cells.  We demonstrated that DZNep 
in combination with TSA induce the expression of AR in AR negative cells (Figure 4.4).  
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 Figure 4.4 Treatment with both a histone methylation and deacetylation inhibitor 
relieves AR expression in PrECs.  All TSA treatments were done at 100nM for the last 
24h of treatment.  Treatment durations are shown (48 or 72h).  (A) Western blot 
presenting the expressional changes following treatment.  (B) Changes in cDNA levels 
resulting from the transcriptional variation elicited by the treatments. 
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We additionally verified a lack of regulation by DNA methylation showing that treatment 
with the DNA methylation inhibitor, 5-aza, failed to rescue AR expression.  A 
comparison of AR gene histone methylation at H3K27 and acetylation between AR 
expressing (LNCaP) and non-expressing (PrEC) may define regions of the AR gene 
undergoing chromosomal compaction during repression.  Also of interest is the 
possibility for a functional chromatin regulating complex associated with DNMT1 and 
E2F1.  Co-immunoprecipitation in addition to coulumn purification experiments would 
examine the potential endogenous interactions between E2F1, DNMT1, EZH2, and 
HDAC (1 and 2).  These studies would further characterize the epigenetic regulation of 
the AR gene. 
 Our findings have brought new insights that challenge the current understandings 
of gene regulation and CRPC.  Contrary to the traditional role of E2F1 in transcriptional 
activation, the regulatory factor was shown to repress AR transcription.  We additionally 
demonstrated that the repression of AR by E2F1 in non-transformed cells was mediated 
by DNMT1 through an unconventional mechanism that is independent of DNA 
methylation.  We further considered how the E2F1/DNMT1 axis might repress AR 
during CRPC.  While many suggest that irregular AR activity contributes to CRPC, we 
provide data supporting a mechanism of AR repression through DNA methylation.  We 
suggest that abnormally high levels of DNMT1 may hypermethylate promoter CGIs and 
repress transcription.  Our studies reveal novel epigenetic regulatory mechanisms 
involved in AR repression that may further contribute to the understanding of 
transcriptional regulation and castration resistant disease.  
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